Document:

Letter Agreement with Dr. Steven B. Ketchum

 Exhibit 10.1 

 
 

 
 12 Roosevelt Ave, 3rd Floor 
 Mystic, CT 06355 
 Tel: 860-572-4979 Fax: 860-572-4940 

February 8, 2012 

Steven B. Ketchum Ph. D 
 49 Canoe
Brook Lane 
 Far Hills, NJ 07931-2808 

Dear Steven: 
 On behalf of
Amarin Corporation plc (the “Company”), I am pleased to offer employment to you. The purpose of this letter is to outline the terms for your employment. 
 1. Position: Your initial position with the Company will be President of Research and Development, Senior Vice President, reporting to Joseph Zakrzewski, Chief Executive Officer. This is a
full-time position as an executive officer of the Company at the Senior Vice President level. It is understood and agreed that, while you render services to the Company, you will not engage in any other employment, consulting or other business
activities (whether full-time or part-time) and that on or before the Start Date you will resign from all other employment and consulting arrangements. Notwithstanding the foregoing, you may engage in religious, charitable, or other community
activities so long as such services or activities do not interfere or conflict with your obligations to the Company. Notwithstanding the foregoing, you may serve on the Board of Directors, as a member or observer, of your previous employer, Sunesis
Pharmaceuticals, Inc. (“Sunesis”), provided such services or activities do not interfere or conflict with your obligations to the Company (“Sunesis Services”), and to the extent there is a scheduling conflict between a Company
event (e.g., phone conference, meeting, etc.) and an event related to the Sunesis Services, the Company event shall take priority. In addition to your role as President of Research and Development, Senior Vice President of the Company, you
acknowledge and agree that you may be required, without additional compensation, to perform duties for certain affiliated entities of the Company, including without limitation Amarin Pharma, Inc., and to accept any reasonable office or position with
any such affiliate as the Company’s Board of Directors may require, including, but not limited to, service as an officer or director of any such affiliate. 
 2. Start Date: Unless otherwise agreed, your first day of employment will be February 16, 2012. Your actual first day of employment shall be referred to herein as the “Start Date.”

 3. Work Location: Your principal place of employment will be the Company’s offices which are currently
located in Bedminster, New Jersey, subject to business travel requirements.  

 

 
 12 Roosevelt Ave, 3rd Floor 
 Mystic, CT 06355 
 Tel: 860-572-4979 Fax: 860-572-4940 

 

 4. Salary: The Company will pay you a salary at the annual rate of $372,000,
subject to periodic review and adjustment at the discretion of the Company. Currently our policy is to make salary payments semi-monthly. 
 5. Bonuses: If your first day of employment with the Company is on or before February 16, 2012, the Company will pay you $31,900 as a signing bonus (the “Signing Bonus”). The Signing
Bonus, if applicable, would be payable to you in a lump sum, less required withholding taxes, within 30 days after your Start Date provided you are then employed with the Company. You will also be eligible to receive annual performance bonuses. The
Company will target the bonus of up to 35% of your annual salary rate. The actual bonus is discretionary and will be subject to the Company’s assessment of your performance, as well as business conditions at the Company. The bonus also will be
subject to your employment for the full period covered by the bonus, approval by and adjustment at the discretion of the Company’s Board of Directors or an authorized committee thereof, and the terms of any applicable bonus plan. The Company
may also make adjustments in the targeted amount of your annual performance bonus. Any bonus awarded to you will be paid by March 15 of the year following the bonus year to which such bonus relates. 

6. Benefits: You will be eligible to participate in the employee benefits and insurance programs generally made available to its
full-time employees, including health, life, disability and dental insurance. You will be eligible for up to fifteen (15) days of paid vacation per year, which shall accrue on a prorated basis. Other provisions of the Company’s vacation
policy are set forth in the policy itself. You will be reimbursed for all reasonable business expenses you incur while carrying out your duties on behalf of the Company; provided such reimbursement shall be conditioned on you following the
Company’s reimbursement policies and claims procedure, including by providing reasonable documentation of such expenses. 

7. Stock Options: The Remuneration Committee of the Board of Directors of the Company (the “Remuneration Committee”) has
authorized the grant to you, subject to your commencement of full-time employment with the Company, a 10-year non-qualified option to purchase 600,000 Ordinary Shares, par value £0.50 per share (and represented by American Depository
Shares, or ADSs), with an exercise price equal to the closing price of the Company’s ADSs on the NASDAQ Capital Market on the date of grant, which in the case of this award shall be the first day of the month following the Start Date that is
also a trading day on the NASDAQ Capital Market. Of these shares 25% shall vest on the one year anniversary of the Start Date with the remaining 75% to vest ratably over the subsequent 36 months. This non-qualified option is intended to qualify as a
so-called “inducement grant” under Nasdaq Marketplace Rule 5635 and as such shall not be issued under the Company’s 2011 Stock Incentive Plan. The terms and conditions of such award shall be set forth in a non-qualified stock option
agreement (the “Equity Document”) that is expected to substantially reflect the various terms and conditions of the Company’s 2011 Stock Incentive Plan (the “2011 Option Plan”). 

  
 2 

 

 
 12 Roosevelt Ave, 3rd Floor 
 Mystic, CT 06355 
 Tel: 860-572-4979 Fax: 860-572-4940 

 

 8. At-will Employment, Accrued Obligations; Severance: Your employment is
“at will” meaning you or the Company may terminate it at any time for any or no reason. In the event of the termination of your employment for any reason, the Company shall pay you the Accrued Obligations, defined as (1) your base
salary through the date of termination, (2) an amount equal to the value of your accrued unused vacation days, if any, and (3) the amount of any business expenses properly incurred by you on behalf of the Company prior to any such
termination and not yet reimbursed, provided if the Repayment Obligation applies you authorize the Company to deduct the Repayment Obligation from the Accrued Obligations to the extent permitted by law and you shall be required to pay the remainder
of the Repayment Obligation, if any, within ten (10) days of the last day of your employment (“Date of Termination”). In addition to the Accrued Obligations, in the event the Company terminates your employment without Cause at any
time, or during the twenty-four (24) month period that immediately follows a Change of Control (the “Post-Change in Control Period”) the Company terminates your employment without Cause or you terminate your employment for Good Reason
(defined below), the Company shall provide you with the following termination benefits (the “Termination Benefits”), depending on the Date of Termination: 
  

	 	(i)	continuation of your base salary then in effect during the “Salary Continuation Period” which shall be either: (A) six (6) months from the Date of
Termination, if the Company terminates your employment without Cause and the Date of Termination occurs at any time outside of the Post-Change in Control Period, or (B) twelve (12) months from the Date of Termination, if the Company
terminates your employment without Cause or you terminate your employment for Good Reason and, in either case, the Date of Termination occurs during the Post-Change in Control Period. Solely for purposes of Section 409A of the Internal Revenue
Code of 1986, as amended, each Salary Continuation Payment during the Salary Continuation Period is considered a separate payment; 

  

	 	(ii)	continuation of group health plan benefits to the extent authorized by and consistent with 29 U.S.C. § 1161 et seq. (commonly known as “COBRA”), with the
cost of the regular premium for such benefits shared in the same relative proportion by the Company and you as in effect on the date of termination until the earlier of: (i) the end of the Salary Continuation Period, and (ii) the date you
become eligible for health benefits through another employer or otherwise become ineligible for COBRA; 

  

	 	(iii)	if the Company terminates your employment without Cause or you terminate your employment for Good Reason and, in either case, the Date of Termination occurs during the
Post-Change in Control Period, a lump sum cash payment equal to your target annual performance bonus for the year during which the Date of Termination occurs; 

  
 3 

 

 
 12 Roosevelt Ave, 3rd Floor 
 Mystic, CT 06355 
 Tel: 860-572-4979 Fax: 860-572-4940 

 

	 	(iv)	if the Company terminates your employment without Cause and the Date of Termination occurs outside of the Post-Change in Control Period, six (6) months of
accelerated vesting from the Date of Termination with respect to any of your then outstanding stock options, restricted stock units or other equity incentive awards (in each case, only to the extent subject to time-based vesting); and

  

	 	(v)	if the Company terminates your employment without Cause or you terminate your employment for Good Reason and, in either case, the Date of Termination occurs during the
Post-Change in Control Period, then outstanding stock options, restricted stock units or other equity incentive awards (whether or not subject to time based vesting) shall immediately vest in full effective upon the Date of Termination.

 Notwithstanding anything to the contrary in this Agreement, you shall not be entitled to any Termination Benefits unless you
first (i) enter into, do not revoke, and comply with the terms of a separation agreement in a form acceptable to the Company which shall include a release of claims against the Company and related persons and entities (the “Release”),
provided that the Release shall not require you to release (a) claims to enforce your right to receive Termination Benefits; (b) claims for vested benefits pursuant to ERISA; (c) claims with respect to your vested equity rights as of
the Date of Termination; (d) claims to enforce the Company’s obligation to indemnify you to the extent such indemnification obligations exist; and (e) claims which legally may not be waived; (ii) resign from any and all
positions, including, without implication of limitation, as a director, trustee, and officer, that you then hold with the Company and any affiliate of the Company; and (iii) return all Company property and comply with any instructions related
to deleting and purging duplicates of such Company property, in each case within the time period designated by the Company but in no event later than 60 days of the Date of Termination. The Salary Continuation Payments shall commence within 60 days
after the Date of Termination and shall be made on the Company’s regular payroll dates; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the Salary Continuation Payments shall begin to
be paid in the second calendar year. In the event you miss a regular payroll period between the Date of Termination and first Salary Continuation Payment, the first Salary Continuation Payment shall include a “catch up” payment.
Notwithstanding the foregoing, if you breach any of the material provisions of this Agreement or the Nondisclosure Developments and Non-competition Agreement, in addition to all other rights and remedies, the Company shall have the right to
terminate or cease payment of the Termination Benefits. For the avoidance of doubt, you shall not be entitled to the Termination Benefits in the event your employment ends due to your death or disability. 

  
 4 

 

 
 12 Roosevelt Ave, 3rd Floor 
 Mystic, CT 06355 
 Tel: 860-572-4979 Fax: 860-572-4940 

 

 9. Definitions: For purposes of this Agreement, the following terms shall have
the following meanings: 
 “Cause” shall mean: (i) conduct by you constituting an act of material misconduct in connection with
the performance of your duties, including, without limitation, misappropriation of funds or property of the Company other than the occasional, customary and de minimis use of Company property for personal purposes; (ii) the commission by you of
(A) any felony; or (B) a misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) any conduct by you that would reasonably be expected to result in material injury or reputational harm to the Company or any of its
subsidiaries and affiliates if you were retained; (iv) continued non-performance or continued unsatisfactory performance by you of your responsibilities as reasonably determined by the Company’s Board of Directors; (v) a breach by you
of any of the material provisions of any agreement between you and the Company including, without limitation, any agreement relating to non-disclosure, non-competition or assignment of inventions; (vi) a material violation by you of any of the
Company’s written policies or procedures provided that, other than in the case of noncurable events, you are provided with written notice and fifteen (15) days to cure. 
 “Change of Control” shall have the meaning set forth in the 2011 Option Plan, but only to the extent such event also constitutes a “change in ownership” of the Company or a
“change in the ownership of a substantial portion of the Company’s assets” for purposes of Section 409A of the Code. 

“Good Reason” shall mean that you have complied with “Good Reason Process” (hereinafter defined) following the occurrence of any of
the following Good Reason conditions that occur without your consent: (i) a material diminution of your base salary; (ii) a material diminution in your authority, duties or responsibilities; (iii) a material change in the principal
location where you are required to provide services for the Company (not including business travel and short-term assignments); and/or (iv) a material breach by the Company of this Agreement. For purposes of this Agreement, “Good Reason
Process” shall mean that: (x) you reasonably determine in good faith that a “Good Reason” condition has occurred; (y) you notify the Company in writing of the Good Reason condition within thirty (30) days of the first
occurrence of such condition; (z) you cooperate in good faith with the Company’s efforts, for a period of thirty (30) days following such notice (the “Cure Period”), to remedy the condition; notwithstanding such efforts, the
Good Reason condition continues to exist; and you terminate your employment within thirty (30) days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have
occurred. 
 10. Section 280G Limitation: Anything in this Agreement to the contrary notwithstanding, in the event
that the amount of any compensation, payment or distribution by the Company to or for the benefit of you, whether paid or payable or distributed or distributable 

  
 5 

 

 
 12 Roosevelt Ave, 3rd Floor 
 Mystic, CT 06355 
 Tel: 860-572-4979 Fax: 860-572-4940 

 

 
pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Code and the applicable regulations thereunder (the “Severance
Payments”), would be subject to the excise tax imposed by Section 4999 of the Code, the following provisions shall apply: 
 (a) If the Severance Payments, reduced by the sum of (1) the Excise Tax and (2) the total of the Federal, state, and local income and employment taxes payable by you on the amount of the
Severance Payments which are in excess of the Threshold Amount, are greater than or equal to the Threshold Amount, you shall be entitled to the full benefits payable under this Agreement. 

(b) If the Threshold Amount is less than (x) the Severance Payments, but greater than (y) the Severance Payments
reduced by the sum of (1) the Excise Tax and (2) the total of the Federal, state, and local income and employment taxes on the amount of the Severance Payments which are in excess of the Threshold Amount, then the Severance Payments shall
be reduced (but not below zero) to the extent necessary so that the sum of all Severance Payments shall not exceed the Threshold Amount. In such event, the Severance Payments shall be reduced in the following order: (1) cash payments not
subject to Section 409A of the Code; (2) cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and (4) non-cash forms of benefits. To the extent any payment is to be made over time
(e.g., in installments, etc.), then the payments shall be reduced in reverse chronological order. 
 (c) For the
purposes of this Section, “Threshold Amount” shall mean three times your “base amount” within the meaning of Section 280G(b)(3) of the Code and the regulations promulgated thereunder less one dollar ($1.00); and “Excise
Tax” shall mean the excise tax imposed by Section 4999 of the Code, and any interest or penalties incurred by you with respect to such excise tax. 
 (d) The determination as to which of the alternative provisions of this Section 9 shall apply to you shall be made by a nationally recognized accounting firm selected by the Company (the
“Accounting Firm”), which shall provide detailed supporting calculations both to the Company and you within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or
you. For purposes of determining which of the alternative provisions of this Section 9 shall apply, you shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the
calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in the state and locality of your residence on the date of termination, net of the maximum reduction in
federal income taxes which could be obtained from deduction of such state and local taxes. Any determination by the Accounting Firm shall be binding upon the Company and you. 

  
 6 

 

 
 12 Roosevelt Ave, 3rd Floor 
 Mystic, CT 06355 
 Tel: 860-572-4979 Fax: 860-572-4940 

 

 11. Taxes; Section 409A: All forms of compensation referred to in this
letter agreement are subject to reduction to reflect applicable withholdings and payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that
minimizes tax liabilities. Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section 409A of the Code, the Company determines that you are a “specified
employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you become entitled to under this Agreement on account of your separation from service would be considered deferred
compensation subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be
provided until the date that is the earlier of (A) six months and one day after your separation from service, or (B) your death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include
a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule.

 All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by
you during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in
which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year.
Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. 
 To the extent that any payment
or benefit described in this Agreement constitutes “non-qualified deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the termination of this Agreement, then such
payments or benefits shall be payable only upon your “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation
Section 1.409A-1(h). 
 The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To
the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. The parties
agree that this Agreement may be 

  
 7 

 

 
 12 Roosevelt Ave, 3rd Floor 
 Mystic, CT 06355 
 Tel: 860-572-4979 Fax: 860-572-4940 

 

 
amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the
payments and benefits provided hereunder without additional cost to either party. 
 The Company makes no representation or warranty and shall
have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.

 12. Representation Regarding Other Obligations: This offer is conditioned on your representation that you are not
subject to any confidentiality, non-competition agreement or any other similar type of restriction that may affect your ability to devote full time and attention to your work at the Company. If you have entered into any agreement that may restrict
your activities on behalf of the Company, please provide me with a copy of the agreement as soon as possible. 
 13. Other
Terms: Your employment with the Company shall be on an at-will basis. In other words, you or the Company may terminate employment for any reason and at any time, with or without notice, subject to the Termination Benefits provisions herein.
Similarly, the terms of employment outlined in this letter are subject to change at any time. You also will be required to sign the Company’s Nondisclosure Developments and Non-competition Agreement as a condition of your employment, the terms
of which shall be incorporated by reference into this letter agreement. A copy of that Agreement is enclosed. In addition, our offer to you is contingent on the completion of references checks and a background investigation that are satisfactory to
the Company (as determined by the Company) and your submission of satisfactory proof of your identity and your legal authorization to work in the United States and a satisfactory Company-paid initial-employment physical and drug screen. 

14. Interpretation, Amendment and Enforcement: This Agreement, including the Company’s Nondisclosure Developments and
Non-competition Agreement and the Equity Document, constitute the complete agreement between you and the Company, contain all of the terms of your employment with the Company and supersede any prior agreements, representations or understandings
(whether written, oral or implied) between you and the Company. The terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement or arising out of, related to, or in any way
connected with, this Agreement, your employment with the Company or any other relationship between you and the Company (the “Disputes”) will be governed by the laws of the State of Connecticut, excluding laws relating to conflicts or
choice of law. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in the State of Connecticut in connection with any Dispute or any claim related to any Dispute. 

  
 8 

 

 
 12 Roosevelt Ave, 3rd Floor 
 Mystic, CT 06355 
 Tel: 860-572-4979 Fax: 860-572-4940 

 

 15. Assignment: Neither you nor the Company may make any assignment of this
Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement without your consent to one of its
Affiliates or to any person with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets. This Agreement shall inure to the benefit of and
be binding upon you and the Company, and each of our respective successors, executors, administrators, heirs and permitted assigns. 
 We are excited about the opportunity to work with you at Amarin. If you have any questions about this information, please do not hesitate to call. Otherwise, please confirm your acceptance of this offer
of employment by signing below and returning a copy to me no later than February 10, 2012. We are confident that with you background and skills, you will have an immediate positive impact on our organization. 

 

			
	Signed for and on behalf of:
	
	AMARIN CORPORATION PLC
		
	Signed:	 	 /s/ Joseph Zakrzewski

		 	Joseph Zakrzewski, Chief Executive Officer
		
	Dated:	 	 February 8, 2012

I accept the offer of employment under the terms and conditions stated above. 

 

			
	Signed:	 	 /s/ Steven B. Ketchum

	Name:	 	Steven B. Ketchum
		
	Dated:	 	 February 8, 2012

 Enclosures 

  
 9Form of purchase agreement

 Exhibit 10.1 
 PURCHASE AGREEMENT 
 THIS PURCHASE AGREEMENT (“Agreement”)
is made as of the      day of February 2012, by and between Acacia Research Corporation (the “Company”), a corporation organized under the laws of the State of Delaware, with its principal offices at 500 Newport
Center Drive, 7th Floor, Newport Beach, CA 92660, and the purchaser whose name and address is set forth on the signature page hereof (the “Purchaser”). 
 IN CONSIDERATION of the mutual covenants contained in this Agreement, the Company and the Purchaser agree as follows: 
 1. Authorization of Sale of the Shares. Subject to the terms and conditions of the Agreements (as defined below), the Company has authorized the issuance and sale of up to 6,122,449 shares (the
“Shares”) of common stock, par value $0.001 per share (the “Common Stock”) of the Company. 

2. Agreement to Sell and Purchase the Shares. At the Closing (as defined in Section 3), the Company will, subject to
the terms of this Agreement, issue and sell to the Purchaser and the Purchaser will buy from the Company, upon the terms and conditions hereinafter set forth, the number of Shares (at the purchase price) shown on the signature page hereof.

 The Company is simultaneously entering into this same form of purchase agreement with certain other investors (the
“Other Purchasers”) and expects to complete sales of the Shares to them. The Purchaser and the Other Purchasers are hereinafter sometimes collectively referred to as the “Purchasers,” and this Agreement and the
purchase agreements executed by the Other Purchasers are hereinafter sometimes collectively referred to as the “Agreements.” The term “Placement Agent” shall mean Barclays Capital Inc., as placement agent.

 3. Delivery of the Shares at the Closing; Termination. 

3.1 Closing. The completion of the purchase and sale of the Shares (the “Closing”) shall occur at the offices of
Stradling Yocca Carlson & Rauth, 660 Newport Center Drive, Suite 1600, Newport Beach, CA 92660, as soon as practicable and as agreed to by the parties hereto, within three business days following the execution of the Agreements, or on such
later date or at such different location as the parties shall agree in writing, but not prior to the date that the conditions for Closing set forth below have been satisfied or waived by the appropriate party (the “Closing Date”).

 3.2 Closing Deliveries. At the Closing, the Purchaser shall deliver, in immediately available funds, the full amount
of the purchase price for the Shares being purchased hereunder by wire transfer to an account designated by the Company and the Company shall deliver to the Purchaser one or more stock certificates, or if the Shares are to be held in book-entry, to
instruct the registrar to register such Shares in the book entry registry, in each case registered in the name of the Purchaser, or in such nominee name(s) as designated by the Purchaser in writing, representing the number of Shares set forth in
Section 2 above and, with respect to certificated shares, bearing an appropriate legend referring to the fact that the Shares were sold in reliance upon the exemption from registration under the Securities Act of 1933, as amended (the
“Securities Act”), provided by Section 4(2) thereof and Rule 506 thereunder. The name(s) in which the stock certificates are to be registered or in which the Shares are to be registered in the book entry registry, if
uncertificated, are set forth in the Stock Certificate or Registry Questionnaire attached hereto as part of Appendix I. 

 3.3 Conditions to the Company’s Obligations. The Company’s obligation to
complete the purchase and sale of the Shares and deliver such stock certificate(s) to the Purchaser at the Closing shall be subject to the following conditions, any one or more of which may be waived by the Company: 

(a) receipt by the Company of same-day funds in the full amount of the purchase price for the Shares being purchased hereunder;

 (b) the closing of purchases of Common Stock by the Other Purchasers equal to at least the Minimum Purchase Amount; for
purposes of this Agreement, the “Minimum Purchase Amount” means such number of shares of Common Stock to be purchased by the Other Purchasers under the Agreements that, when combined with the number of Shares to be purchased by the
Purchaser pursuant to this Agreement and multiplied by the price at which those shares and the Shares are to be purchased, is equal to $100,000,000; 
 (c) the accuracy of the representations and warranties made by the Purchasers and the fulfillment of those undertakings of the Purchasers to be fulfilled prior to the Closing; and 

(d) receipt by the Company from the Purchaser of the fully completed questionnaires attached hereto as Appendix I.

 3.4 Conditions to the Purchaser’s Obligations. The Purchaser’s obligation to accept delivery of such stock
certificate(s) and to pay for the Shares evidenced thereby shall be subject to the following conditions, any one or more of which may be waived by the Purchaser: 
 (a) the closing of purchases of Common Stock by the Other Purchasers equal to at least the Minimum Purchase Amount; 
 (b) each of the representations and warranties of the Company made herein shall be accurate as of the Closing Date; 
 (c) the delivery to the Purchaser by counsel to the Company of legal opinions substantially similar in substance to the forms of opinion attached as Exhibit B hereto; 

(d) receipt by the Placement Agent, on each of the date hereof and the Closing Date, a letter dated the date hereof or the Closing Date,
as the case may be, in form and substance satisfactory to the Placement Agent, from Grant Thornton LLP (i) confirming that they are independent public accountants within the meaning of the Securities Act and are in compliance with the
applicable requirements relating to the qualification of accountants under Rule 2-01 of Regulation S-X of the Rules and Regulations and (ii) containing statements and information of the type ordinarily included in accountants’
“comfort letters” to underwriters in registered public offering with respect to the financial statements and certain financial information contained in the Private Placement Memorandum, excluding any financial statements and financial
information contained in the Private Placement Memorandum, to the extent relating to Adaptix, Inc. 

  
 2 

 (e) receipt by the Purchaser of a certificate executed by the chief executive officer and
the chief financial or accounting officer of the Company, dated as of the Closing Date, to the effect that the representations and warranties of the Company set forth herein are true and correct as of the date of this Agreement and as of such
Closing Date and that the Company has complied with all the agreements and satisfied all the conditions herein on its part to be performed or satisfied on or prior to such Closing Date; 

(f) receipt by the Purchaser of a certificate of the Secretary of the Company, dated as of the Closing Date: 

(i) certifying the resolutions adopted by the Board of Directors of the Company approving the transactions contemplated by this
Agreement and the issuance of the Shares; 
 (ii) certifying the current versions of the Amended and Restated Certificate of
Incorporation and the Amended and Restated Bylaws of the Company; and 
 (iii) certifying as to the signatures and authority of
the persons signing this Agreement and related documents on behalf of the Company; 
 (g) receipt by the Purchaser of a
certificate of good standing for the Company for its jurisdiction of incorporation and a certificate of qualification as a foreign corporation for the Company for any jurisdictions in which it is qualified to transact business as a foreign
corporation; 
 (h) receipt by the Purchaser of a certificate from the Company’s transfer agent certifying the number of
shares of Common Stock outstanding as of the Closing Date; 
 (i) there shall have been no suspensions in the trading of the
Common Stock as of the Closing Date; 
 (j) the Common Stock shall continue to be listed on The Nasdaq Global Select Market as
of the Closing Date and the Shares shall be approved for listing on The Nasdaq Global Select Market as of the Closing Date, subject to official notice of issuance; and 
 (k) the fulfillment in all material respects of those undertakings of the Company to be fulfilled prior to the Closing. 
 3.5 Termination. This Agreement shall automatically terminate if the Closing has not occurred prior to February 24, 2012. Without limiting the generality of the foregoing, in event of such
termination, neither party shall have any obligation to sell or purchase the Shares. 
 4. Representations, Warranties and
Covenants of the Company. The Company hereby represents and warrants to, and covenants with, the Purchaser as follows: 

4.1 Organization and Qualification. The Company is a corporation duly incorporated, validly existing and in good standing under
the laws of the State of Delaware, and the Company is qualified to transact business as a foreign corporation in each jurisdiction in which qualification is required, except where the failure to so qualify would neither have nor reasonably be
expected to have a Material Adverse Effect (as defined in Section 4.6). Each subsidiary (as defined 

  
 3 

 
under Rule 405 promulgated under the Securities Act) of the Company (each, a “Subsidiary” and collectively, the “Subsidiaries”) is listed on
Exhibit A to this Agreement. Except as otherwise set forth on Exhibit A, each Subsidiary is a direct or indirect wholly owned subsidiary of the Company. Each Subsidiary is duly organized, validly existing and in good standing
under the laws of its jurisdiction of organization and is qualified to transact business as a foreign corporation in each jurisdiction in which qualification is required, except where failure to so qualify would neither have nor reasonably be
expected to have a Material Adverse Effect. 
 4.2 Reporting Company; Form S-3. The Company is not an “ineligible
issuer” (as defined in Rule 405 promulgated under the Securities Act) and is eligible to register the resale of the Shares by the Purchaser on a registration statement on Form S-3 under the Securities Act. The Company is subject to the
reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and has filed all reports required thereby during the past 12 calendar months. Provided that none of the Purchasers is deemed to be an
underwriter with respect to any shares, and except for the filing of any Acquisition 8-K (as defined herein) or any other matters referenced in Section 7.1(a), to the Company’s knowledge, there exist no facts or circumstances
(including without limitation any required approvals or waivers or any circumstances that may delay or prevent the obtaining of accountant’s consents) that reasonably could be expected to prohibit the preparation and filing of a registration
statement on Form S-3 that will be available for the resale of the Shares by the Purchaser. 
 4.3 Authorized Capital
Stock. The Company had duly authorized and validly issued outstanding capitalization as set forth in the SEC Documents (as defined in Section 4.19) as of the date set forth therein; the issued and outstanding shares of Common Stock
(a) have been duly authorized and validly issued, (b) are fully paid and nonassessable, (c) have been issued in compliance with all federal and state securities laws and, (d) except for those granted therein by the holders
thereof (other than the Company), are free and clear of all security interests, liens, pledges, mortgages or other encumbrances, whether arising voluntarily, involuntarily or by operation of law (“Liens”), (e) were not issued
in violation of or subject to any preemptive rights or other rights to subscribe for or purchase securities, and (f) conform in all material respects to the description thereof contained in the SEC Documents. Except as set forth in SEC
Documents and except for the stock options or other equity incentives that have been issued since September 30, 2011, the Company does not have outstanding any options to purchase, or any preemptive rights or other rights to subscribe for or to
purchase, any securities or obligations convertible into, or any contracts or commitments to issue or sell, shares of its capital stock or any such options, rights, convertible securities or obligations. The issuance and sale of the Shares will not,
immediately or with the passage of time, obligate the Company to issue shares of Common Stock or other securities to any Person (other than the Purchasers) and will not result in a right of any holder of Company securities to adjust the exercise,
conversion, exchange or reset price under such securities. With respect to each of the Subsidiaries, (i) all of the issued and outstanding shares of such Subsidiary’s capital stock (or equity interests in the case of non-corporate
entities) have been duly authorized and validly issued, are fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, were not issued in violation of or subject to any preemptive rights or other rights
to subscribe for or purchase securities, and (ii) there are no outstanding options to purchase, or any preemptive rights or other rights to subscribe for or to purchase, any securities or obligations convertible into, or any contracts or
commitments to issue or sell, shares of such Subsidiary’s capital stock or any such options, rights, convertible securities or obligations. 

  
 4 

 4.4 Issuance, Sale and Delivery of the Shares. The issuance and sale of the Shares
have been duly authorized by the Company and the Shares, when issued, delivered and paid for in the manner set forth in this Agreement, will be validly issued, fully paid and nonassessable, and will conform in all material respects to the
description thereof set forth in the SEC Documents. No preemptive rights or other rights to subscribe for or purchase any shares of Common Stock of the Company exist with respect to the issuance and sale of the Shares by the Company pursuant to this
Agreement that have not been waived or complied with. No stockholder of the Company has any right (which has not been waived or has not expired by reason of lapse of time following notification of the Company’s intention to file the
Registration Statement (as hereinafter defined)) to require the Company to register the sale of any capital stock owned by such stockholder under the Registration Statement. No further approval or authority of the Company’s stockholders or the
Board of Directors of the Company will be required for the issuance and sale of the Shares to be sold by the Company as contemplated herein. 
 4.5 Due Execution, Delivery and Performance of the Agreements. The Company has full legal right, corporate power and authority to enter into this Agreement and perform the transactions contemplated
hereby. This Agreement has been duly authorized, executed and delivered by the Company. This Agreement constitutes a legal, valid and binding agreement of the Company, enforceable against the Company in accordance with its terms, except as
enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws and judicial decisions of general application relating to or affecting the enforcement of creditors’ rights generally and the
application of general equitable principles relating to the availability of remedies, and except as rights to indemnity or contribution, including but not limited to, indemnification provisions set forth in Section 7.3 of this Agreement,
may be limited by federal or state securities law or the public policy underlying such laws. The execution and performance of this Agreement by the Company and the consummation of the transactions herein contemplated will not violate any provision
of the Amended and Restated Certificate of Incorporation or Amended and Restated Bylaws of the Company or the organizational documents of any Subsidiary and will not result in the creation of any Liens upon any assets of the Company or any
Subsidiary pursuant to the terms or provisions of, or will not conflict with, result in the breach or violation of, or constitute, either by itself or upon notice or the passage of time or both, a default under any agreement, mortgage, deed of
trust, lease, franchise, license, indenture, permit or other instrument to which any of the Company or any Subsidiary is a party or by which any of the Company or any Subsidiary or their respective properties may be bound or affected and in each
case that would have or reasonably be expected to have a Material Adverse Effect, any statute or any authorization, judgment, decree, order, rule or regulation of any court or any regulatory body, administrative agency or other governmental agency
or body applicable to the Company or any Subsidiary or any of their respective properties. No consent, approval, authorization or other order of any court, regulatory body, administrative agency or other governmental agency or body is required for
the execution and delivery of this Agreement by the Company or the consummation by the Company of the transactions contemplated by this Agreement, except for compliance with the Blue Sky laws and federal securities laws applicable to the offering of
the Shares and such as may be required by the bylaws and rules of the Financial Industry Regulatory Authority, Inc. or The Nasdaq Global Select Market. For the purposes of this Agreement, the term “Material Adverse Effect” shall
mean any material adverse effect on the business, properties, assets, operations, results of operations, condition (financial or otherwise) or prospects of the Company and its Subsidiaries, taken as a whole, or on the transactions contemplated
hereby or by the agreements and instruments to be entered into in connection herewith or therewith, or on the authority or ability of the Company to perform its obligations hereunder. 

  
 5 

 4.6 Accountants. Grant Thornton LLP, who has reported on the consolidated financial
statements and schedules contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2010 (which are incorporated by reference into the confidential private placement memorandum dated February 9, 2012
(together with any exhibits, amendments and supplements thereto and all information incorporated by reference therein, the “Private Placement Memorandum”)), are registered independent public accountants as required by the Securities
Act and the rules and regulations promulgated thereunder (the “1933 Act Rules and Regulations”) and by the rules of the Public Accounting Oversight Board. 
 4.7 No Defaults or Consents. Neither the execution, delivery and performance of this Agreement by the Company nor the consummation of any of the transactions contemplated hereby (including, without
limitation, the issuance and sale by the Company of the Shares) will give rise to a right to terminate or accelerate the due date of any payment due under, or conflict with or result in the breach of any term or provision of, or constitute a default
(or an event that with notice or lapse of time or both would constitute a default) under, except such defaults that individually or in the aggregate would neither cause nor reasonably be expected to cause a Material Adverse Effect, or require any
consent or waiver under, or result in the execution or imposition of any Liens upon any properties or assets of the Company or its Subsidiaries pursuant to the terms of, any indenture, mortgage, deed of trust or other agreement or instrument to
which the Company or any of its Subsidiaries is a party or by which either the Company or its Subsidiaries or any of its or their properties or businesses is bound, or any franchise, license, permit, judgment, decree, order, statute, rule or
regulation applicable to the Company or any of its Subsidiaries or violate any provision of the charter or by-laws of the Company or any of its Subsidiaries, except for such consents or waivers that have already been obtained and are in full force
and effect. 
 4.8 Contracts. The material contracts to which the Company is a party that have been filed as exhibits to
the SEC Documents (as defined in Section 4.19), have been duly and validly authorized, executed and delivered by the Company and constitute the legal, valid and binding agreements of the Company, enforceable by and against it in
accordance with their respective terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws and judicial decisions of general application relating to enforcement of
creditors’ rights generally, and the application of general equitable principles relating to or affecting the availability of remedies, and except as rights to indemnity or contribution may be limited by federal or state securities laws or the
public policy underlying such laws. 
 4.9 No Actions. There are no legal or governmental actions, suits or proceedings
pending or, to the Company’s knowledge, threatened against the Company or any Subsidiary before or by any court, regulatory body or administrative agency or any other governmental agency or body, domestic or foreign, which actions, suits or
proceedings, individually or in the aggregate, would have or reasonably be expected to have a Material Adverse Effect; and no labor disturbance by the employees of the Company exists or, to the Company’s knowledge, is imminent, that would have
or reasonably be expected to have a Material Adverse Effect. Neither the Company nor any Subsidiary is a party to or subject to the provisions of any injunction, judgment, decree or order of any court, regulatory body, administrative agency or other
governmental agency or body that would have or reasonably be expected to have a Material Adverse Effect. 
 4.10
Properties. The Company and each Subsidiary has good and valid title to all items of tangible personal property described as owned by it in the consolidated financial statements included in the Private Placement Memorandum that are material
to the businesses of the Company 

  
 6 

 
and its Subsidiaries taken as a whole, in each case free and clear of all Liens except for those disclosed in the SEC Documents, or those, individually or in the aggregate, that (i) do not
materially interfere with the use made and proposed to be made of such property by the Company and its Subsidiaries or (ii) would neither have nor reasonably be expected to have a Material Adverse Effect. Any real property described in the
Private Placement Memorandum as being leased by the Company or any Subsidiary that is material to the business of the Company and its Subsidiaries, taken as a whole, is held by them under valid, existing and enforceable leases, except those that,
individually or in the aggregate, (A) do not materially interfere with the use made or proposed to be made of such property by the Company and its Subsidiaries or (B) would neither have nor reasonably be expected to have a Material Adverse
Effect. 
 4.11 No Material Adverse Change. Except as disclosed in the SEC Documents, since December 31, 2010
(i) the Company and its Subsidiaries have not incurred any material liabilities or obligations, indirect or contingent, or entered into any material agreement or other transaction that is not in the ordinary course of business or that could
reasonably be expected to result in a material reduction in the future earnings of the Company; (ii) the Company and its Subsidiaries have not sustained any material loss or material interference with their businesses or properties from fire,
flood, windstorm, accident or other calamity not covered by insurance; (iii) the Company and its Subsidiaries have not paid or declared any dividends or other distributions with respect to their capital stock and none of the Company or any
Subsidiary is in material default in the payment of principal or interest on any outstanding long-term debt obligations; (iv) there has not been any change in the capital stock of the Company or its Subsidiaries other than the sale of the
Shares hereunder and shares or options issued pursuant to employee equity incentive plans or purchase plans approved by the Company’s Board of Directors, or indebtedness material to the Company or its Subsidiaries (other than in the ordinary
course of business and any required scheduled payments); and (v) there has not occurred any event that has caused or would reasonably be expected to cause a Material Adverse Effect. 

4.12 Intellectual Property. Except as disclosed in the Private Placement Memorandum or the SEC Documents, (i) the Company and
each Subsidiary owns or has obtained valid and enforceable licenses or options for the inventions, patent applications, patents, trademarks (both registered and unregistered), trade names, copyrights and trade secrets necessary for the conduct of
its respective business as currently conducted (collectively, the “Intellectual Property”); and (ii) (a) there are no third parties who have any ownership rights or other ownership claims to any Intellectual Property that
is owned by, or has been licensed to, the Company or any Subsidiary for the products and services of the Company and its Subsidiaries described in the Private Placement Memorandum or the SEC Documents that would preclude the Company or any
Subsidiary from conducting its business as currently conducted and have or reasonably be expected to have a Material Adverse Effect, except for the ownership rights of the owners of the Intellectual Property licensed or optioned by the Company or
any Subsidiary; (b) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others challenging the rights of the Company or any Subsidiary in or to any Intellectual Property owned, licensed or
optioned by the Company or any Subsidiary, other than claims that would neither have nor reasonably be expected to have a Material Adverse Effect; (c) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding
or claim by others challenging the validity or scope of any Intellectual Property owned, licensed or optioned by the Company or any Subsidiary, other than actions, suits, proceedings and claims that would neither have nor reasonably be expected to
have a Material Adverse Effect; and (d) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others that the Company or any Subsidiaries infringes or otherwise violates

  
 7 

 
any patent, trademark, copyright, trade secret or other proprietary right of others, other than actions, suits, proceedings and claims that would neither have nor reasonably be expected to have a
Material Adverse Effect. 
 4.13 Compliance. Neither the Company nor any of its Subsidiaries have been advised, nor do
any of them have any reason to believe, that it is not conducting business in compliance with all applicable laws, rules and regulations of the jurisdictions in which it is conducting business, including, without limitation, all applicable local,
state and federal environmental laws and regulations, except where failure to be so in compliance would neither have nor reasonably be expected to have a Material Adverse Effect. 

4.14 Taxes. The Company and each Subsidiary has filed all required tax returns, and all such tax returns are true, correct and
complete in all material respects. The Company and each Subsidiary has fully paid all taxes shown as due thereon. None of the Company or any Subsidiary has knowledge of any deficiency or assessment with respect to liabilities for any material taxes
that has been or might be asserted or threatened against it, which has not been fully paid or finally settled, unless being contested in good faith through appropriate proceedings and for which adequate reserves are reflected in the Company’s
consolidated financial statements. All tax liabilities accrued through the date hereof have been adequately reserved for in the Company’s consolidated financial statements. 

4.15 Transfer Taxes. On the Closing Date, all stock transfer or other taxes (other than income taxes) that are required to be paid
in connection with the transactions contemplated by this Agreement will be, or will have been, fully paid by the Company and all laws imposing such taxes will be or will have been fully complied with. 

4.16 Investment Company. The Company is not an “investment company” or “promoter” or “principal
underwriter” for an investment company, within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Securities and Exchange Commission (the “Commission”) promulgated thereunder.

 4.17 Offering Materials. None of the Company, its directors and officers has distributed or will distribute prior to
the Closing Date any offering material, including, without limitation, any “free writing prospectus” (as defined in Rule 405 promulgated under the Securities Act), in connection with the offering and sale of the Shares other than the
Private Placement Memorandum or any amendment or supplement hereto. The Company has not in the past nor will it hereafter take any action independent of the Placement Agent to sell, offer for sale or solicit offers to buy any securities of the
Company that could result in the initial sale of the Shares not being exempt from the registration requirements of Section 5 of the Securities Act. 
 4.18 Insurance. The Company maintains insurance underwritten by insurers of recognized financial responsibility, of the types and in the amounts that the Company reasonably believes is adequate for
its business, including, but not limited to, insurance covering all real and personal property owned or leased by the Company against theft, damage, destruction, acts of vandalism and all other risks customarily insured against, with such
deductibles as are customary for companies in the same or similar business, all of which insurance is in full force and effect. 

4.19 Additional Information. The information contained in the following documents (the “SEC Documents”), which
the Placement Agent has furnished to the Purchaser (or 

  
 8 

 
will furnish prior to the Closing) or which are otherwise available through the Commission’s EDGAR system, as of the dates thereof, did not contain an untrue statement of a material fact or
omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances in which they were made, not misleading: 

(a) the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010; 

(b) the Company’s Amended Annual Report on Form 10-K/A for the fiscal year ended December 31, 2010, filed March 24, 2011;

 (c) the Company’s Definitive Proxy Statement for the Annual Meeting of Stockholders held on May 17, 2011, filed
April 8, 2011; 
 (d) the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2011,
filed April 29, 2011; 
 (e) the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30,
2011, filed August 1, 2011; 
 (f) the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended
September 30, 2011, filed October 28, 2011; 
 (g) the description of the Company’s common stock contained in
its Registration Statement on Form 8-A filed on May 11, 1995, as amended by Amendment No. 1 to Registration Statement on Form 8-A filed on June 5, 1995, Amendment No. 2 to Registration Statement on Form 8-A filed on
December 30, 1999, and its Registration Statement on Form 8-A filed on December 19, 2002, as amended by Amendment No. 1 to Registration Statement on Form 8-A filed on August 14, 2008; and 

(h) all other documents, if any, filed by the Company (excluding the Current Reports on Form 8-K or the portions thereof furnished under
Item 2.02 or Item 7.01 of Form 8-K) with the Commission since December 31, 2010 pursuant to the reporting requirements of the Exchange Act. 
 The SEC Documents incorporated by reference in the Private Placement Memorandum or attached as exhibits thereto, at the time they became effective or were filed with the Commission, as the case may be,
complied in all material respects with the requirements of the Exchange Act, as applicable, and the rules and regulations of the Commission thereunder (the “1934 Act Rules and Regulations” and, together with the 1933 Act Rules and
Regulations, the “Rules and Regulations”). In the past 12 calendar months, the Company has filed all documents required to be filed by it prior to the date hereof with the Commission pursuant to the reporting requirements of the
Exchange Act and the 1934 Act Rules and Regulations. 
 4.20 Price of Common Stock. The Company has not taken, and will
not take, directly or indirectly, any action designed to cause or result in, or that has constituted or that might reasonably be expected to constitute, the stabilization or manipulation of the price of the shares of the Common Stock to facilitate
the sale or resale of the Shares. 

  
 9 

 4.21 Use of Proceeds. The Company shall use the proceeds from the sale of the Shares
as described under “Use of Proceeds” in the Private Placement Memorandum. 
 4.22 Use of Purchaser Name. Except
as otherwise required by applicable law or regulation, neither the Company nor any of its subsidiaries, shall use the Purchaser’s name or the name of any of its Affiliates (as defined below) in any advertisement, announcement, press release or
other similar public communication or in any communications with third parties unless it has received the prior written consent of the Purchaser for the specific use contemplated. For purposes of this Agreement, “Affiliate” means,
with respect to any natural person, firm, partnership, association, corporation, limited liability company, company, trust, entity, public body or government (a “Person”), any Person that, directly or indirectly, controls, is
controlled by, or is under common control with, such Person. The term “control” (including the terms “controlled by” and “under common control with”) as used in this definition means the possession, directly or
indirectly, of the power to direct or cause the direction of management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. With respect to any natural person, the term “Affiliate” means
(i) the spouse or children (including those by adoption) and siblings of such Person; and any trust whose primary beneficiary is such Person, such Person’s spouse, such Person’s siblings and/or one or more of such Person’s lineal
descendants, (ii) the legal representative or guardian of such Person or of any such immediate family member in the event such Person or any such immediate family member becomes mentally incompetent and (iii) any Person controlled by or
under common control with any one or more of such Person and the Persons described in clauses (i) or (ii) preceding. 

4.23 Related-Party Transactions. No transaction has occurred between or among the Company, on the one hand, and its Affiliates,
officers or directors on the other hand, that is required to have been described under applicable securities laws and the rules and regulations promulgated thereunder in its Exchange Act filings and is not so described in such filings. 

4.24 Non Public Information. Except as disclosed in the Private Placement Memorandum, the Company has not disclosed to the
Purchaser information that would constitute material non-public information as of the Closing Date other than the existence of the transactions contemplated hereby. 
 4.25 Off-Balance Sheet Arrangements. There is no transaction, arrangement or other relationship between the Company and an unconsolidated or other off-balance sheet entity that is required to be
disclosed by the Company in its Exchange Act filings and is not so disclosed or that otherwise would have or would reasonably be expected to have a Material Adverse Effect. There are no such transactions, arrangements or other relationships with the
Company that may create any material contingencies or liabilities that are not otherwise disclosed by the Company in its Exchange Act filings. 
 4.26 Governmental Permits, Etc. The Company and each Subsidiary has all franchises, licenses, certificates and other authorizations from federal, state or local governments or governmental
agencies, departments or bodies that are currently necessary for the operation of the business of the Company and its Subsidiaries as currently conducted, except where the failure to possess currently such franchises, licenses, certificates and
other authorizations would neither have nor reasonably be expected to have a Material Adverse Effect. Neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any such permit that,
if the subject of an unfavorable decision, ruling or finding, would have or would reasonably be expected to have a Material Adverse Effect. 

  
 10 

 4.27 Financial Statements. The consolidated financial statements of the Company and
the related notes and schedules thereto included in its Exchange Act filings present fairly, in all material respects, the financial condition of the Company and its consolidated Subsidiaries as of the dates thereof and the results of operations,
stockholders’ equity and cash flows of the Company and its consolidated Subsidiaries at the dates and for the periods covered thereby. Such financial statements and the related notes and schedules thereto have been prepared in accordance with
generally accepted accounting principles consistently applied throughout the periods involved (except as otherwise noted therein) and all adjustments necessary for a fair presentation of results for such periods have been made; provided, however,
that the unaudited financial statements are subject to normal year-end audit adjustments (which are not expected to be material) and do not contain all footnotes required under generally accepted accounting principles. 

4.28 Listing Compliance. The Company is in compliance with the requirements of The Nasdaq Global Select Market for continued
listing of the Common Stock thereon. The Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or the listing of the Common Stock on The Nasdaq Global Select
Market, nor has the Company received any notification that the Commission or The Nasdaq Global Select Market is currently contemplating terminating such registration or listing. The transactions contemplated by this Agreement will not contravene the
rules and regulations of The Nasdaq Global Select Market. The Company will comply with all requirements of The Nasdaq Global Select Market with respect to the issuance of the Shares and shall cause the Shares to be listed on The Nasdaq Global Select
Market and listed on any other exchange on which the Common Stock is listed on or before (subject to official notice of issuance) the Closing Date. 
 4.29 Internal Accounting Controls. The Company maintains a system of internal accounting controls sufficient to provide reasonable assurances that (i) transactions are executed in accordance
with management’s general or specific authorization; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain accountability for
assets; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and
appropriate action is taken with respect to any differences. The Company maintains disclosure controls and procedures (as defined in Rules 13a-15 and 15d-15 under the Exchange Act) that are designed to ensure that material information relating to
the Company is made known to the Company’s principal executive officer and the Company’s principal financial officer or persons performing similar functions. There is and has been no failure on the part of the Company, or to its knowledge
after due inquiry, any of the Company’s directors or officers, in their capacities as such, to comply with any applicable provisions of the Sarbanes Oxley Act of 2002 and the rules and regulations promulgated therewith (the “Sarbanes
Oxley Act”). Each of the principal executive officer and the principal financial officer of the Company (or each former principal executive officer of the Company and each former principal financial officer of the Company as applicable) has
made all certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act with respect to all reports, schedules, forms, statements and other documents required to be filed by it with the Commission. For purposes of the preceding
sentence, “principal executive officer” and “principal financial officer” shall have the meanings given to such terms in the Sarbanes-Oxley Act. The Company has taken all reasonable actions necessary to ensure that it is in
compliance with all provisions of the Sarbanes-Oxley Act that are in effect and with which the Company is required to comply. 

  
 11 

 4.30 Foreign Corrupt Practices. Neither the Company nor any Subsidiary has, nor, to
the knowledge of the Company, has any director, officer, agent or employee, in the course of its actions for, or on behalf of, the Company (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful
expenses relating to political activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; (iii) violated or is in violation of any provision of the U.S.
Foreign Corrupt Practices Act of 1977, as amended; or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government official or employee. 

4.31 Employee Relations. Neither the Company nor any Subsidiary is a party to any collective bargaining agreement or employs any
member of a union (other than with regards to statutory unions required under foreign laws and regulations). The Company and each Subsidiary believe that their relations with their employees are good. No executive officer of the Company (as defined
in Rule 501(f) promulgated under the Securities Act) has notified the Company that such officer intends to leave the Company or otherwise terminate such officer’s employment with the Company. No executive officer of the Company is, or is now
expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement, non-competition agreement or any other agreement or any restrictive covenant, and the continued
employment of each such executive officer does not subject the Company or any Subsidiary to any liability with respect to any of the foregoing matters. 
 4.32 ERISA. Each material employee benefit plan, within the meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), that is
maintained, administered or contributed to by the Company or any of its Affiliates for employees or former employees of the Company and its Subsidiaries, or to which the Company or any of its Subsidiaries has any liability thereunder (a
“Company Benefit Plan”), has been maintained in material compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Internal Revenue Code of
1986, as amended (the “Code”); no action, dispute, claim, suit or proceeding is pending or, to the knowledge of the Company, threatened with respect to any Company Benefit Plan (other than claims for benefits in the ordinary course)
that could reasonably be expected to result in a material liability to the Company; no prohibited transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred that could reasonably be expected to result
in a material liability to the Company with respect to any such plan excluding transactions effected pursuant to a statutory or administrative exemption; and for each such plan that is subject to the funding rules of Section 412 of the Code or
Section 302 of ERISA, no “accumulated funding deficiency” as defined in Section 412 of the Code has been incurred, whether or not waived, and the fair market value of the assets of each such plan (excluding for these purposes
accrued but unpaid contributions) exceeds the present value of all benefits accrued under such plan determined using reasonable actuarial assumptions. 
 4.33 Environmental Matters. There has been no storage, disposal, generation, manufacture, transportation, handling or treatment of toxic wastes, hazardous wastes or hazardous substances by the
Company or to its knowledge, any Subsidiary (or, to the knowledge of the Company, any of their predecessors in interest) at, upon or from any of the property now or previously owned or leased by the Company or any Subsidiary in material violation of
any applicable law, ordinance, rule, regulation, order, judgment, decree or permit or that would require remedial 

  
 12 

 
action under any applicable law, ordinance, rule, regulation, order, judgment, decree or permit; there has been no material spill, discharge, leak, emission, injection, escape, dumping or release
of any kind into such property or into the environment surrounding such property of any toxic wastes, medical wastes, solid wastes, hazardous wastes or hazardous substances due to or caused by the Company or any Subsidiary or with respect to which
the Company or any Subsidiary have knowledge; the terms “hazardous wastes”, “toxic wastes”, “hazardous substances”, and “medical wastes” shall have the meanings specified in any applicable local, state,
federal and foreign laws or regulations with respect to environmental protection. 
 4.34 Integration; Other Issuances of
Shares. The Company has not issued any shares of Common Stock or shares of any series of preferred stock or other securities or instruments convertible into, exchangeable for or otherwise entitling the holder thereof to acquire shares of Common
Stock that would be integrated with the sale of the Shares to the Purchaser for purposes of the Securities Act or of any applicable stockholder approval provisions, including, without limitation, under the rules and regulations of any exchange or
automated quotation system on which any of the securities of the Company are listed or designated. Assuming the accuracy of the representations and warranties of the Purchasers to the Company as set forth herein, the offer and sale of the Shares to
the Purchasers pursuant to the Agreements will be exempt from the registration requirements of the Securities Act. 
 4.35
Disclosure. All disclosure provided to the Purchaser, including, without limitation, the Private Placement Memorandum, regarding the Company, its business and the transactions contemplated hereby, furnished by or on behalf of the Company,
were, as of the date made, true and correct and did not contain any untrue statement of material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were
made, not misleading. 
 4.36 No New Issuances and Registrations. The Company agrees that until the 90th day after the
Closing Date, or if the Registration Statement (as defined herein) is not declared effective within 60 days of the Closing Date, then for an additional period of 30 days from the date the Registration Statement is declared effective, it will not,
and it will cause its directors, officers and Affiliates not to (except in the case of the directors and officers of the Company, pursuant to exceptions set forth in lock-up letter agreements entered into between the Placement Agent and such
directors and officers), directly or indirectly, grant, issue, sell, pledge or otherwise dispose of any shares of Common Stock, or securities convertible into or exchangeable for Common Stock, or file a registration statement with respect to the
registration of any such newly issued shares of Common Stock or other securities, or amend or modify the rights, preferences, privileges or other terms of any securities of the Company outstanding on the date hereof. Notwithstanding the above, the
restrictions set forth in this Section 4.36 shall not apply to issuances by the Company of (i) securities required to be issued pursuant to contractual obligations of the Company in effect as of the date hereof; (ii) securities
issued on a pro rata basis to all holders of a class of outstanding equity securities of the Company; (iii) securities issued in connection with any bona fide merger, acquisition or other business combination, joint venture, equipment leasing
arrangement or other strategic or commercial relationship, so long as the aggregate amount of such issuances pursuant to this clause (iii) does not exceed 15% of the Company’s outstanding capital stock measured as of the closing of the
sale of the Shares, including the Shares; and (iv) equity securities issued pursuant to employee compensation, incentive, benefit or purchase plans in effect as of the date hereof or subsequently adopted by the Company’s Board of
Directors. Notwithstanding the foregoing, the Company shall not, and shall cause its directors, officers and Affiliates not to, sell, offer for sale or solicit offers to 

  
 13 

 
buy any shares of Common Stock or shares of any series of preferred stock or other securities or instruments convertible into, exchangeable for or otherwise entitling the holder thereof to
acquire shares of Common Stock that would be integrated with the sale of the Shares to the Purchaser for purposes of the Securities Act. 
 4.37 No Undisclosed Events, Liabilities, Developments or Circumstances. Except for the transactions contemplated hereby, which will be disclosed in the Press Release (as defined in
Section 7.1(i) below), and except as otherwise disclosed to the Purchaser, which will be publicly disclosed prior to the filing of the Registration Statement, no event, liability, development or circumstance has occurred or exists, or is
contemplated to occur, with respect to the Company or its Subsidiaries or their respective business, properties, prospects, operations or financial condition, that would be required to be disclosed by the Company under applicable securities laws on
a registration statement on Form S-1 filed with the SEC relating to an issuance and sale by the Company of its Common Stock and which has not been publicly announced. 
 4.38 Shell Company Status. The Company is not, and has never been, an issuer identified in Rule 144(i)(1) of the Securities Act. 

4.39 No General Solicitation; Valid Private Placement. Neither the Company, nor any of its Subsidiaries or Affiliates, nor any
Person acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D under the Securities Act) in connection with the offer or sale of the Shares. The offer and issuance by
the Company of the Shares is exempt from registration under the Securities Act. 
 4.40 Most Favored Nations. 

(a) For so long as the Purchaser is bound by the terms of this Agreement, any provision of any purchase agreement with any Other
Purchaser or other agreement or side letter, or any amendment, modification or addition thereto, entered into by and among any Other Purchaser and the Company, presently or at any time in the future (collectively, “Company
Agreements”), that has the effect of establishing rights or otherwise benefiting any such Other Purchaser in a manner more favorable in any material respect (any such material rights or benefits, “Preferred Terms”) that the
rights and benefits established in favor of the Purchaser by this Agreement, shall become part of this Agreement, for the benefit of the Purchaser. 
 (b) The Company confirms and represents that: (1) all Company Agreements shall be in writing, (2) it has provided the Purchaser with copies of all Company Agreements (which contain Preferred
Terms) existing as of the date of this Agreement, and (3) it shall provide the Purchaser with copies of all Company Agreements (which contain Preferred Terms) which may be entered into on or after the date hereof within five (5) calendar
days after execution thereof; provided, that the Company may redact the names of the parties to such Company Agreements. 
 5.
Representations, Warranties and Covenants of the Purchaser. The Purchaser represents and warrants to, and covenants with, the Company that: 
 5.1 Experience. (i) The Purchaser is knowledgeable, sophisticated and experienced in financial and business matters, in making, and is qualified to make, decisions with respect to investments
in shares representing an investment decision like that involved in the 

  
 14 

 
purchase of the Shares, including, without limitation, investments in securities issued by the Company and comparable entities, and the Purchaser has undertaken an independent analysis of the
merits and the risks of an investment in the Shares and has reviewed carefully the Private Placement Memorandum, based on the Purchaser’s own financial circumstances; (ii) the Purchaser has had the opportunity to request, receive, review
and consider all information it deems relevant in making an informed decision to purchase the Shares and to ask questions of, and receive answers from, the Company concerning such information; (iii) the Purchaser is acquiring the number of
Shares set forth on the signature page hereto in the ordinary course of its business and for its own account and with no present intention of distributing any of such Shares or any arrangement or understanding with any other Persons regarding the
distribution of such Shares (this representation and warranty not limiting the Purchaser’s right to resell the Shares pursuant to the Registration Statement or in compliance with the Securities Act and the Rules and Regulations, or, other than
with respect to any claims arising out of a breach of this representation and warranty, the Purchaser’s right to indemnification under Section 7.3); (iv) the Purchaser will not, directly or indirectly, offer, sell, pledge
(other than pledges in connection with bona fide margin accounts), transfer or otherwise dispose of (or solicit any offers to buy, purchase or otherwise acquire or take a pledge of (other than pledges in connection with bona fide margin accounts))
any of the Shares, nor will the Purchaser engage in any short sale that results in a disposition of any of the Shares by the Purchaser, except in compliance with the Securities Act and the Rules and Regulations and any applicable state securities
laws as currently interpreted on the date hereof; (v) the Purchaser will comply with the prospectus delivery requirements of the Securities Act as applicable to it in connection with resales of the Shares pursuant to the Registration Statement
or with the applicable requirements of any exemption from the Securities Act; (vi) the Purchaser has completed or caused to be completed the Registration Statement Questionnaire attached hereto as part of Appendix I, for use in
preparation of the Registration Statement, and the answers thereto are true and correct as of the date hereof and will be true and correct as of the effective date of the Registration Statement (the “Effective Date”), unless the
Purchaser notifies the Company otherwise, and the Purchaser agrees to update the information set forth in the Registration Statement Questionnaire upon the reasonable request of the Company and to notify the Company immediately of any material
change in the information provided in the Registration Statement Questionnaire, other than a material change in the number of Shares held by the Purchaser, until such time as the Purchaser has sold all of its Shares or until the Company is no longer
required to keep the Registration Statement effective; (vii) the Purchaser has, in connection with its decision to purchase the number of Shares set forth in Section 2 above, relied solely upon the SEC Documents, the Private
Placement Memorandum and the representations and warranties of the Company contained herein, and the Purchaser has not relied on the Placement Agent in negotiating the terms of its investment in the Shares and, in making a decision to purchase the
Shares, the Purchaser has not received or relied on any communication, investment advice or recommendation from the Placement Agent; (viii) the Purchaser has had an opportunity to discuss this investment with representatives of the Company and
ask questions of them but has not relied on any communication (other than the Private Placement Memorandum) or recommendation from any representative of the Company and (ix) the Purchaser is an institutional investor that is an
“institutional accredited investor” (an “Accredited Investor”) within the meaning of Rule 501(a)(1), (2), (3) or (7) under the Securities Act, as modified by the Dodd-Frank Wall Street Reform and Consumer
Protection Act (Pub. L. 111-203, H.R. 4173). 
 5.2 Reliance on Exemptions. The Purchaser understands that the Shares are
being offered and sold to it in reliance upon specific exemptions from the registration requirements of the Securities Act, the Rules and Regulations and state securities laws and that the Company is relying upon the truth and accuracy of, and the
Purchaser’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility of the Purchaser to
acquire the Shares. 

  
 15 

 5.3 Confidentiality. For the benefit of the Company, the Purchaser previously agreed
with the Placement Agent to keep confidential all information concerning this private placement. The Purchaser is prohibited from reproducing or distributing this Agreement, the Private Placement Memorandum or any other offering materials or other
information provided by the Company in connection with the Purchaser’s consideration of its investment in the Company, in whole or in part, or divulging or discussing any of their contents, except to its financial, investment or legal advisors
in connection with its proposed investment in the Shares. Further, the Purchaser understands that the existence and nature of all conversations and presentations, if any, regarding the Company and this offering must be kept strictly confidential.
The Purchaser understands that the federal securities laws impose restrictions on trading based on information regarding this offering. In addition, the Purchaser hereby acknowledges that unauthorized disclosure of information regarding this
offering may result in a violation of Regulation FD. This obligation will terminate upon the filing by the Company of the Press Release (as defined below), which shall include any material, non-public information provided to the Purchaser prior to
the date hereof. The foregoing agreements shall not apply to any information that is or becomes publicly available through no fault of the Purchaser, or that the Purchaser is legally required to disclose; provided, however, that if the
Purchaser is requested or ordered to disclose any such information pursuant to any court or other government order or any other applicable legal procedure, it shall provide the Company with prompt notice of any such request or order in time
sufficient to enable the Company to seek an appropriate protective order. 
 5.4 Investment Decision. The Purchaser
understands that nothing in the Agreement or any other materials presented to the Purchaser in connection with the purchase and sale of the Shares constitutes legal, tax or investment advice. The Purchaser has consulted such legal, tax and
investment advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with its purchase of the Shares. 
 5.5 Risk of Loss. The Purchaser understands that its investment in the Shares involves a significant degree of risk, including a risk of total loss of the Purchaser’s investment, and the
Purchaser has full cognizance of and understands all of the risk factors related to the Purchaser’s purchase of the Shares, including, but not limited to, those set forth and incorporated by reference under the caption “Risk Factors”
in the Private Placement Memorandum. The Purchaser understands that the market price of the Common Stock has been volatile and that no representation is being made as to the future value of the Common Stock. 

5.6 Legend; Legend Removal. The Purchaser understands that, until such time as the Registration Statement has been declared
effective, or the Shares are sold pursuant to Rule 144 under the Securities Act without any restriction as to the number of securities as of a particular date that can then be immediately sold, the Shares, to the extent certificated, will bear
a restrictive legend in substantially the following form: 
 “THE SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. THE SHARES MAY NOT BE OFFERED, SOLD,

  
 16 

 
PLEDGED OR OTHERWISE TRANSFERRED EXCEPT (1) PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OR (2) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE
SECURITIES ACT, IN EACH CASE IN ACCORDANCE WITH ALL APPLICABLE STATE SECURITIES LAWS AND THE SECURITIES LAWS OF OTHER JURISDICTIONS, AND IN THE CASE OF A TRANSACTION EXEMPT FROM REGISTRATION, UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL
REASONABLY SATISFACTORY TO IT THAT SUCH TRANSACTION DOES NOT REQUIRE REGISTRATION UNDER THE SECURITIES ACT OR THE COMPANY HAS RECEIVED FROM THE HOLDER REASONABLE ASSURANCE THAT THE SHARES CAN BE SOLD, ASSIGNED OR TRANSFERRED PURSUANT TO RULE 144
UNDER THE SECURITIES ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.” 

The legend set forth above shall be removed and the Company shall issue a certificate without such legend, within three (3) Trading
Days (as defined below) after the occurrence of any of (i) through (iii) below, to the holder of the Shares upon which it is stamped or issue such Shares to such holder by electronic delivery at the applicable balance account at The
Depository Trust Company (“DTC”), if, unless otherwise required by state securities laws, (i) the Registration Statement covering registered resales of such Shares has been declared effective under the Securities Act and such
Registration Statement remains effective under such Act, or (ii) in connection with any sale, assignment or other transfer of Shares that is not to be effected pursuant to such Registration Statement, such holder first provides the Company with
an opinion of counsel reasonably satisfactory to the Company, in a generally acceptable form, to the effect that such sale, assignment or transfer of the Shares may be made without registration under the applicable requirements of the Securities Act
and that such legend is no longer required, or (iii) such holder first provides the Company with reasonable assurance that the Shares can be sold, assigned or transferred pursuant to Rule 144. The Company shall be responsible for the fees
of its transfer agent and all DTC fees associated with such issuance. If the Company shall fail for any reason or for no reason to issue to the holder of the Shares within five (5) Trading Days after the occurrence of any of (i) through
(iii) above and following the delivery by such holder to the Company in accordance with Section 10 hereof or to the Company’s transfer agent (with a copy delivered to the Company in accordance with Section 10
hereof) of a certificate representing Shares issued with a restrictive legend, a certificate without such legend to such holder or to issue such Shares to such holder by electronic delivery at the applicable balance account at DTC, and if on or
after such Trading Day such holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by such holder of such Shares that the holder anticipated receiving without legend from the Company
(a “Buy-In”), then the Company shall, within five (5) Trading Days after such holder’s request and in such holder’s discretion, either (i) pay cash to such holder in an amount equal to such holder’s total
purchase price (including brokerage commissions, if any) for the shares of Common Stock actually purchased by such holder (the “Buy-In Price”), at which point the Company’s obligation to deliver such unlegended Shares shall
terminate and such holder shall transfer to the Company title to such Shares and hereby agrees to execute and deliver to the Company such documentation as the 

  
 17 

 
Company may reasonably request to reflect such transfer, or (ii) promptly honor its obligation to deliver to the holder such unlegended Shares as provided above and pay cash to the holder in
an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of shares of Common Stock, times (B) the closing bid price of the Common Stock on the date such legend-free Shares were required to have been
delivered. For purposes of the Agreement, “Trading Day” means a day on which the Common Stock is traded on The Nasdaq Global Select Market or, if the Common Stock is not then traded on The Nasdaq Global Select Market, the principal
market or exchange on which the Common Stock is then listed or quoted for trading. 
 Notwithstanding the foregoing, in the
event that the Shares are in an uncertificated form and registered directly on the Company’s share registry, the Company’s transfer agent will not permit transfers of such shares except in compliance with the restrictions contained in this
Section 5.6. 
 The Company acknowledges and agrees that, so long as Shares owned by the Purchaser remain
“restricted securities” within the meaning of Rule 144 and have not been sold pursuant to the Registration Statement, the Purchaser may from time to time pledge some or all of such Shares pursuant to a bona fide margin agreement with
a registered broker-dealer that is a qualified institutional buyer as defined in Rule 144A under the Securities Act (a “QIB”) or an Accredited Investor or grant a security interest in some or all of such Shares to a financial
institution that is a QIB or an Accredited Investor (each such pledgee or transferee, a “Qualifying Institution”), provided in each case that the terms of the applicable pledge or security interest shall require as a condition to
any transfer of Shares to a Qualifying Institution pursuant to such pledge or security interest that such Qualifying Institution agree to be bound by the provisions of this Agreement (including without limitation complying with the restrictions on
transfer set forth herein and agreeing not to make any sale of the Shares under the Registration Statement without complying with the provisions of this Agreement and without effectively causing the prospectus delivery requirement under the
Securities Act to be satisfied). The Purchaser shall not be required to give notice to the Company of such pledge or granting of a security interest, but, in accordance with Section 7.2 hereof, shall promptly furnish to the Company upon
request a copy of such instrument or instrument of transfer evidencing the assignee’s or transferee’s agreement to be bound by the provisions of this Agreement (including Section 11 hereof). If required under the terms of the
Purchaser’s arrangement with such Qualifying Institution, the Purchaser may transfer any such pledged or secured Shares to such Qualifying Institution, provided such transfer is made in compliance with the Securities Act and the 1933 Act Rules
and Regulations and any applicable state securities laws. Such transfer would not be subject to approval by the Company, and no legal opinion of legal counsel of the Qualifying Institution would be required in connection therewith. At the
Purchaser’s expense, the Company will execute and deliver such reasonable documentation as such Qualifying Institution may reasonably request in connection with a transfer of such Shares, including, if appropriate, the preparation and filing of
any required prospectus supplement under Rule 424(b)(3) under the Securities Act or other applicable provision of the Securities Act to appropriately amend the list of selling stockholders thereunder to include such Qualifying Institution as a
selling stockholder therein. 
 5.7 Stop Transfer. The Shares will be subject to a stop transfer order with the
Company’s transfer agent prior to the time that the resale Registration Statement on Form S-3 is effective, which order restricts the transfer of such shares, except in circumstances in which the Company is permitted to suspend the
effectiveness of the Registration Statement as permitted herein and with notice provided to the Purchaser of such stop transfer order in accordance with Section 10. 

  
 18 

 5.8 Residency. The Purchaser’s principal executive offices are in the
jurisdiction set forth immediately below the Purchaser’s name on the signature pages hereto. 
 5.9 Public Sale or
Distribution. The Purchaser hereby covenants with the Company not to make any sale of the Shares under the Registration Statement without complying with the provisions of this Agreement and without effectively causing the prospectus delivery
requirement under the Securities Act to be satisfied (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule). The Purchaser acknowledges that there may occasionally be times when the Company must
suspend the use of the prospectus (the “Prospectus”) forming a part of the Registration Statement (a “Suspension”) until such time as an amendment to the Registration Statement has been filed by the Company and
declared effective by the Commission, or until such time as the Company has filed an appropriate report with the Commission pursuant to the Exchange Act. Without the Company’s prior written consent, which consent shall not unreasonably be
withheld or delayed, the Purchaser shall not use any written materials to offer the Shares for resale other than the Prospectus, including any “free writing prospectus” as defined in Rule 405 under the Securities Act. The Purchaser
covenants that it will not sell any Shares pursuant to said Prospectus during the period commencing at the time when the Company gives the Purchaser written notice of Suspension of the use of said Prospectus and ending at the time when the Company
gives the Purchaser written notice that the Purchaser may thereafter effect sales pursuant to said Prospectus. In each such notice, the Company shall not disclose the content of any material, non-public information to the Purchaser. The Purchaser
shall maintain in confidence the receipt of any notice of Suspension. Notwithstanding the foregoing, the Company agrees that no Suspension shall be for a period in excess of fifteen (15) consecutive days, and during any three hundred sixty-five
(365) day period, the aggregate of all of the Suspensions shall not exceed an aggregate of thirty (30) days, and the first day of any Suspension shall be at least five (5) trading days after the last day of any prior Suspension (each,
an “Allowable Suspension Period”). 
 5.10 Organization; Validity; Enforcements. The Purchaser further
represents and warrants to, and covenants with, the Company that (i) the Purchaser has full right, power, authority and capacity to enter into this Agreement and to consummate the transactions contemplated hereby and has taken all necessary
action to authorize the execution, delivery and performance of this Agreement, (ii) the making and performance of this Agreement by the Purchaser and the consummation of the transactions herein contemplated will not violate any provision of the
organizational documents of the Purchaser or conflict with, result in the breach or violation of, or constitute, either by itself or upon notice or the passage of time or both, a default under any material agreement, mortgage, deed of trust, lease,
franchise, license, indenture, permit or other instrument to which the Purchaser is a party or, any statute or any authorization, judgment, decree, order, rule or regulation of any court or any regulatory body, administrative agency or other
governmental agency or body applicable to the Purchaser, (iii) no consent, approval, authorization or other order of any court, regulatory body, administrative agency or other governmental agency or body is required on the part of the Purchaser
for the execution and delivery of this Agreement or the consummation of the transactions contemplated by this Agreement, (iv) upon the execution and delivery of this Agreement, this Agreement shall constitute a legal, valid and binding
obligation of the Purchaser, enforceable in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws or judicial decisions of general application
relating to or affecting the enforcement of creditors’ rights generally and the application of equitable principles relating to the availability of remedies, and except as rights to indemnity or contribution, including, but not limited to, the
indemnification provisions set forth in Section 7.3 of this Agreement, may be limited by federal or state securities laws or the public policy underlying such laws and (v) there is not in effect any order enjoining or restraining
the Purchaser from entering into or engaging in any of the transactions contemplated by this Agreement. 

  
 19 

 5.11 Short Sales. Since the time the Purchaser was first contacted about the offering
of the Shares and the transactions contemplated hereby, the Purchaser has not taken, and prior to the public announcement of the transaction the Purchaser shall not take, any action that has caused or will cause the Purchaser to have, directly or
indirectly, sold or agreed to sell any shares of Common Stock, effected any short sale, whether or not against the box, established any “put equivalent position” (as defined in Rule 16a-1(h) under the Exchange Act) with respect to the
Common Stock, granted any other right (including, without limitation, any put or call option) with respect to the Common Stock or with respect to any security that includes, relates to or derived any significant part of its value from the Common
Stock. 
 6. Survival of Agreements; Non-Survival of Company Representations and Warranties. Notwithstanding any
investigation made by any party to this Agreement or by the Placement Agent, all representations, warranties, covenants and agreements made by the Company and the Purchaser herein and in the certificates for the Shares delivered pursuant hereto
shall survive the execution of this Agreement, the delivery to the Purchaser of the Shares being purchased and the payment therefor. 
 7. Registration of the Shares; Compliance with the Securities Act. 
 7.1
Registration Procedures and Expenses. The Company shall: 
 (a) as soon as reasonably practicable, but in no event later
than five business days following the later of (a) the date the Company files each Current Report on Form 8-K, or an amendment thereto on Form 8-K/A, containing the financial statements and information required by Item 9.01 of Form 8-K
(each, an “Acquisition 8-K”) with respect to any acquisition that has been completed as of the date hereof, and, to the extent applicable, any pending acquisition which is contemplated pursuant to a written letter of intent entered
into by the Company and the proposed acquisition target as of the date hereof (a “Pending Acquisition”), (b) the date the Company files its Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and
(c) the date the Company terminates all negotiations with respect to any Pending Acquisition that would require it to file an Acquisition 8-K (the “Filing Deadline”), prepare and file with the Commission the Registration
Statement on Form S-3 relating to the resale of the Shares by the Purchaser and the Other Purchasers from time to time on The Nasdaq Global Select Market, or the facilities of any national securities exchange on which the Common Stock is then
traded or in privately-negotiated transactions; 
 (b) use its reasonable best efforts, subject to receipt of necessary
information from the Purchasers, to cause the Commission to declare the Registration Statement effective by the earlier of (i) 3 days after the Commission has advised the Company that the Registration Statement has not been selected for review
by the Commission, (ii) 3 days after the Commission has advised the Company the Commission has no more comments with respect to the Registration Statement or (iii) 90 days after the Closing Date (each of (i), (ii) and (iii), the
“Effectiveness Deadline”); 
 (c) by 9:30 a.m., New York City time, on the second business day following the
date the Registration Statement is declared effective by the Commission, the Company shall file with the Commission in accordance with Rule 424 under the Securities Act the final prospectus to be used in connection with sales pursuant to such
Registration Statement; 

  
 20 

 (d) promptly prepare and file with the Commission such amendments and supplements to the
Registration Statement and the prospectus used in connection therewith as may be necessary to keep the Registration Statement effective until the earlier of (i) the date as of which the Investors may sell all of the Shares covered by such
Registration Statement without restriction pursuant to Rule 144 and without the requirement to be in compliance with Rule 144(c)(1) (or any successor thereto) promulgated under the Securities Act or (ii) the date on which the Investors shall
have sold all of the Shares covered by the Registration Statement. For the purpose of this Agreement, “Investor” means a Purchaser or any transferee or assignee thereof to whom a Purchaser assigns its rights as a holder of Shares
under this Agreement and who agrees to become bound by the provisions of this Agreement and any transferee or assignee thereof to whom a transferee or assignee assigns its rights as a holder of Shares under this Agreement and who agrees to become
bound by the provisions of this Agreement; 
 (e) furnish to the Purchaser with respect to the Shares registered under the
Registration Statement (and to each underwriter, if any, of such Shares) such number of copies of prospectuses and such other documents as the Purchaser may reasonably request, in order to facilitate the public sale or other disposition of all or
any of the Shares by the Purchaser; 
 (f) file documents required of the Company for normal Blue Sky clearance in states
specified in writing by the Purchaser; provided, however, that the Company shall not be required to qualify to do business or consent to service of process in any jurisdiction in which it is not now so qualified or has not so
consented; 
 (g) bear all expenses in connection with the procedures in paragraphs (a) through (e) of this
Section 7.1 and the registration of the Shares pursuant to the Registration Statement, other than fees and expenses, if any, of counsel or other advisers to the Purchaser or the Other Purchasers or underwriting discounts, brokerage fees
and commissions incurred by the Purchaser or the Other Purchasers, if any, in connection with the offering of the Shares pursuant to the Registration Statement; 
 (h) file a Form D with the Commission with respect to the Shares as required under Regulation D promulgated under the Securities Act and to provide a copy thereof to the Purchaser promptly after
filing; 
 (i) issue a press release describing the transactions contemplated by this Agreement and any other material
non-public information that was disclosed to the Purchaser (the “Press Release”) on or before 8:30 a.m., New York City time, on the first business day following the date hereof; and 

(j) except as otherwise contemplated hereunder, the Company shall not, and shall cause each of its Subsidiaries and each of their
respective officers, directors, employees and agents not to, provide any Purchaser with any material, non-public information regarding the Company or any of its Subsidiaries from and after the filing of the Press Release without the express written
consent of such Purchaser; 

  
 21 

 (k) in order to enable the Purchasers to sell the Shares under Rule 144 under the
Securities Act, for a period of one year from Closing, use its reasonable best efforts to comply with the requirements of Rule 144, including without limitation, use its reasonable best efforts to comply with the requirements of
Rule 144(c) with respect to public information about the Company and to timely file all reports required to be filed by the Company under the Exchange Act; and 
 (l) permit the Purchaser and its legal counsel to review and comment upon (i) an initial draft of a Registration Statement at least two (2) business days prior to its filing with the Commission
and (ii) any numbered pre-effective amendment to such Registration Statement (for purposes of clarification, excluding any Annual Report on Form 10-K, Quarterly Report on Form 10-Q, Current Report on Form 8-K or other public
filing incorporated by reference into such Registration Statement) at least one (1) business day prior to its filing with the Commission. The Company shall furnish to the Purchaser or its legal counsel, without charge, copies of any
correspondence from the Commission to the Company or its representatives relating to the Registration Statement. 
 The Company
understands that the Purchaser disclaims being an underwriter, but the Purchaser being deemed an underwriter shall not relieve the Company of any obligations it has hereunder. Neither the Company nor any Subsidiary or Affiliate thereof shall
identify the Purchaser as an underwriter in any public disclosure or filing with the Commission or any stock exchange or market without the prior written consent of Purchaser. The forms of the questionnaires related to the Registration Statement to
be completed by the Purchaser are attached hereto as Appendix I. 
 For purposes of this Section 7.1 and
for purposes of Sections 7.3(d), 7.6 and 18 hereof, the definition of “Shares” shall include any capital stock of the Company issued or issuable with respect to the Shares as a result of any stock split, stock
dividend, recapitalization, exchange or similar event or otherwise. 
 7.2 Transfer of Shares After Registration. The
Purchaser agrees that it will not effect any disposition of the Shares or its right to purchase the Shares that would constitute a sale within the meaning of the Securities Act or pursuant to any applicable state securities laws, except pursuant to
the Registration Statement referred to in Section 7.1, in accordance with Rule 144 under the Securities Act or as otherwise permitted by law, and that it will promptly notify the Company of any changes in the information set forth
in the Registration Statement regarding the Purchaser or its plan of distribution. 
 7.3 Indemnification. For the
purpose of this Section 7.3: 
 (i) the term “Purchaser Indemnified Persons” shall mean each
Investor, director, officer, member, partner, employee, agent and representative of the Investor and each Person, if any, who controls any Investor within the meaning of the Securities Act or the Exchange Act; and 

(ii) the term “Registration Statement” shall include any preliminary prospectus, final prospectus, free writing
prospectus, exhibit, supplement or amendment included in or relating to, and any document incorporated by reference in, the Registration Statement referred to in Section 7.1. 

  
 22 

 (a) The Company agrees to indemnify and hold harmless the Purchaser Indemnified Persons,
against any losses, claims, damages, liabilities or expenses, joint or several, to which the Purchaser Indemnified Persons may become subject, under the Securities Act, the Exchange Act, or any other federal or state statutory law or regulation, or
at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of the Company), insofar as such losses, claims, damages, liabilities or expenses (or actions in respect thereof as
contemplated below) arise out of or are based upon (i) any untrue statement or alleged untrue statement of any material fact contained in the Registration Statement, including, without limitation, the Prospectus, financial statements and
schedules, and all other documents filed as a part thereof, as amended at the time of effectiveness of the Registration Statement, including, without limitation, any information deemed to be a part thereof as of the time of effectiveness pursuant to
paragraph (b) of Rule 430A, or pursuant to Rules 430B, 430C or 434, of the 1933 Act Rules and Regulations, or the Prospectus, in the form first filed with the Commission pursuant to Rule 424(b) of the 1933 Act Rules and Regulations, or filed as
part of the Registration Statement at the time of effectiveness if no Rule 424(b) filing is required or any amendment or supplement thereto, or that arise out of or are based upon the omission or alleged omission to state in any of them a material
fact required to be stated therein or necessary to make the statements in the Registration Statement or any amendment or supplement thereto not misleading or in the Prospectus or any amendment or supplement thereto not misleading in light of the
circumstances under which they were made; provided, however, that the Company will not be liable for amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of
the Company, which consent shall not be unreasonably withheld or delayed, and the Company will not be liable in any such case to the extent that any such loss, claim, damage, liability or expense arises out of or is based upon (A) an untrue
statement or alleged untrue statement or omission or alleged omission made in the Registration Statement, the Prospectus or any amendment or supplement thereto in reliance upon and in conformity with written information furnished to the Company by
or on behalf of the Purchaser expressly for use therein, (B) the failure of the Purchaser to comply with the covenants and agreements contained herein or (C) the inaccuracy of any representation or warranty made by the Purchaser herein,
(ii) any misrepresentation or breach of any representation or warranty made by the Company in the Agreement or any other certificate, instrument or document contemplated hereby or thereby, (iii) any breach of any covenant, agreement or
obligation of the Company contained in the Agreement or any other certificate, instrument or document contemplated hereby or thereby or (iv) any cause of action, suit or claim brought or made against such Purchaser Indemnified Person by a third
party (including for these purposes a derivative action brought on behalf of the Company) and arising out of or resulting (A) from the execution, delivery, performance or enforcement of the Agreement or any other certificate, instrument or
document contemplated hereby or thereby, (B) from any transaction financed or to be financed in whole or in part, directly or indirectly, with the proceeds of the issuance of the Shares or (C) solely from the status of such Purchaser or
holder of the Shares as an investor in the Company, and the Company will promptly reimburse the Purchaser Indemnified Persons for reasonable legal and other expenses as such expenses are reasonably incurred by the Purchaser Indemnified Persons in
connection with investigating, defending or preparing to defend, settling, compromising or paying any such loss, claim, damage, liability, expense or action. 
 (b) The Purchaser and Other Purchasers will severally, but not jointly, indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement and each
person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act (a “Control Person”), against any losses, claims, damages, liabilities or expenses to which
the Company, each of its directors, each of 

  
 23 

 
its officers who signed the Registration Statement or Control Person may become subject, under the Securities Act, the Exchange Act, or any other federal or state statutory law or regulation, or
at common law or otherwise (including in settlement of any litigation, but only if such settlement is effected with the written consent of the Purchaser) insofar as such losses, claims, damages, liabilities or expenses (or actions in respect thereof
as contemplated below) arise out of or are based upon any untrue or alleged untrue statement of any material fact contained in the Registration Statement, the Prospectus, or any amendment or supplement thereto, or that arise out of or are based upon
the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements in the Registration Statement or any amendment or supplement thereto not misleading or in the Prospectus or any
amendment or supplement thereto not misleading in the light of the circumstances under which they were made, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission
was made in the Registration Statement, the Prospectus, or any amendment or supplement thereto, in reliance upon and in conformity with written information furnished to the Company by or on behalf of the Purchaser expressly for use therein; and will
reimburse the Company, each of its directors, each of its officers who signed the Registration Statement and each such Control Person for any legal and other expense reasonably incurred by the Company, each of its directors, each of its officers who
signed the Registration Statement or Control Person, as the case may be, in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action; provided, however, that
the Purchaser’s aggregate liability under this Section 7 shall not exceed the amount of net proceeds received by the Purchaser on the sale of the Shares pursuant to the Registration Statement. 

(c) Promptly after receipt by an indemnified party under this Section 7.3 of notice of the threat or commencement of any
action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this Section 7.3, promptly notify the indemnifying party in writing thereof, but the omission to notify the indemnifying
party will not relieve it from any liability that it may have to any indemnified party for contribution or otherwise under the indemnity agreement contained in this Section 7.3 to the extent it is not prejudiced as a result of such
failure. In case any such action is brought against any indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it
may wish, jointly with all other indemnifying parties similarly notified, to assume the defense thereof with counsel reasonably satisfactory to such indemnified party; provided, however, if the defendants in any such action include
both the indemnified party and the indemnifying party, and the indemnified party shall have reasonably concluded, based on an opinion of counsel reasonably satisfactory to the indemnifying party, that there may be a conflict of interest between the
positions of the indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and/or other indemnified parties that are different from or additional to those available
to the indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties. Upon
receipt of notice from the indemnifying party to such indemnified party of its election to assume the defense of such action and approval by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party under
this Section 7.3 for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i) the indemnified party shall have employed such counsel in connection with the
assumption of legal defenses in accordance with the proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the expenses of more than one separate counsel, reasonably satisfactory to such
indemnifying 

  
 24 

 
party, representing all of the indemnified parties who are parties to such action) or (ii) the indemnifying party shall not have employed counsel reasonably satisfactory to the indemnified
party to represent the indemnified party within a reasonable time after notice of commencement of action, in each of which cases the reasonable fees and expenses of counsel shall be at the expense of the indemnifying party. In no event shall any
indemnifying party be liable in respect of any amounts paid in settlement of any action unless the indemnifying party shall have approved in writing the terms of such settlement; provided that such consent shall not be unreasonably withheld
or delayed. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is or could have been a party and
indemnification could have been sought hereunder by such indemnified party from all liability on claims that are the subject matter of such proceeding. 
 (d) If the indemnification provided for in this Section 7.3 is required by its terms but is for any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified
party under paragraphs (a), (b) or (c) of this Section 7.3 in respect to any losses, claims, damages, liabilities or expenses referred to herein, then each applicable indemnifying party shall contribute to the amount paid or
payable by such indemnified party as a result of any losses, claims, damages, liabilities or expenses referred to herein (i) in such proportion as is appropriate to reflect the relative benefits received by the Company and the Purchaser from
the private placement of Common Stock hereunder or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause
(i) above but the relative fault of the Company and the Purchaser in connection with the statements or omissions or inaccuracies in the representations and warranties in this Agreement and/or the Registration Statement that resulted in such
losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Purchaser on the other shall be deemed to be in the same proportion as
the amount paid by the Purchaser to the Company pursuant to this Agreement for the Shares purchased by the Purchaser that were sold pursuant to the Registration Statement bears to the difference (the “Difference”) between the amount
the Purchaser paid for the Shares that were sold pursuant to the Registration Statement and the amount received by the Purchaser from such sale. The relative fault of the Company on the one hand and the Purchaser on the other shall be determined by
reference to, among other things, whether the untrue or alleged statement of a material fact or the omission or alleged omission to state a material fact or the inaccurate or the alleged inaccurate representation and/or warranty relates to
information supplied by the Company or by the Purchaser and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The amount paid or payable by a party as a result of
the losses, claims, damages, liabilities and expenses referred to above shall be deemed to include, subject to the limitations set forth in paragraph (c) of this Section 7.3, any legal or other fees or expenses reasonably incurred
by such party in connection with investigating or defending any action or claim. The provisions set forth in paragraph (c) of this Section 7.3 with respect to the notice of the threat or commencement of any threat or action shall
apply if a claim for contribution is to be made under this paragraph (d); provided, however, that no additional notice shall be required with respect to any threat or action for which notice has been given under paragraph (c) for
purposes of indemnification. The Company and the Purchaser agree that it would not be just and equitable if contribution pursuant to this Section 7.3 were determined solely by pro rata allocation (if the Purchaser were treated as one
entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to in this paragraph. Notwithstanding the provisions of this Section 7.3, the Purchaser shall not be
required to contribute any amount in excess of the amount by which the Difference exceeds the amount of any damages that the Purchaser has otherwise been 

  
 25 

 
required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. Notwithstanding the provisions of this Section 7.3, the Purchaser shall not be
required to contribute any amount in excess of the amount of net proceeds received by such Purchaser from the sale of its Shares pursuant to the Registration Statement, less any other payments made by such Purchaser pursuant to this
Section 7.3. No Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. The
Purchasers’ obligations to contribute pursuant to this Section 7.3 are several and not joint. 
 7.4
Termination of Conditions and Obligations. 
 (a) The restrictions imposed by Section 5.9 or
Section 7.2 upon the transferability of the Shares shall (1) cease and terminate as to any particular number of the Shares upon the earlier of (A) the passage of one year from the Effective Date of the Registration Statement
covering such Shares and (B) at such time as an opinion of counsel satisfactory in form and substance to the Company shall have been rendered to the effect that such conditions are not necessary in order to comply with the Securities Act, and
(2) not apply in connection with any transfer to an Affiliate of the Purchaser so long as such Affiliate transferee shall agree in writing to be bound by the terms of this Agreement. 

(b) Notwithstanding anything in this Agreement to the contrary, in connection with any transfer of Shares to an Affiliate of the
Purchaser, the Purchaser shall not be required to provide the Company an opinion of counsel. 
 7.5 Information
Available. The Company, upon the reasonable request of the Purchaser, shall make available for inspection by each Purchaser, any underwriter participating in any disposition pursuant to the Registration Statement and any attorney, accountant or
other agent retained by the Purchaser or any such underwriter, all financial and other records, pertinent corporate documents and properties of the Company, and cause the Company’s officers, employees and independent accountants to supply all
information reasonably requested by the Purchaser or any such underwriter, attorney, accountant or agent in connection with the Registration Statement, and all such information provided by the Company pursuant to this Section 7.5 shall
be subject to the confidentiality obligations imposed by Section 5.3. 
 7.6 Delay in Filing or Effectiveness of
Registration Statement; Public Information. 
 (a) If (i) a Registration Statement covering all of the Shares required
to be covered thereby and required to be filed by the Company pursuant to this Agreement is (A) not filed with the SEC on or before the respective Filing Deadline (a “Filing Failure”) or (B) not declared effective by the
SEC on or before the Effectiveness Deadline (an “Effectiveness Failure”) or (ii) on any day after the Effective Date sales of all of the Shares required to be included on such Registration Statement cannot be made (other than
during an Allowable Suspension Period (as defined in Section 5.9)) pursuant to such Registration Statement or otherwise (including, without limitation, because of a failure to keep such Registration Statement effective, to disclose such
information as is necessary for sales to be made pursuant to such Registration Statement or to register a sufficient number of shares of Common Stock or to maintain the listing of the shares of Common Stock) (a “Maintenance
Failure”) then, as partial relief for the damages to any Investor by reason of any such delay in or reduction of its ability to sell the underlying shares of Common Stock (which 

  
 26 

 
remedy shall not be exclusive of any other remedies available at law or in equity), the Company shall pay to each Investor relating to such Registration Statement an amount in cash equal to
(A) one percent (1.0%) of the aggregate Purchase Price of such Investor’s Shares included in such Registration Statement on each of the following dates: (i) the day of a Filing Failure and on every thirtieth day (pro rated for
periods totaling less than thirty (30) days) thereafter until the date such Filing Failure is cured; (ii) the day of an Effectiveness Failure and on every thirtieth day (pro rated for periods totaling less than thirty (30) days)
thereafter until the date such Effectiveness Failure is cured; and (iii) the initial day of a Maintenance Failure and on every thirtieth day (pro rated for periods totaling less than thirty (30) days) thereafter until the date such
Maintenance Failure is cured. The payments to which an Investor shall be entitled to pursuant to this Section 7.6 are referred to herein “Registration Delay Payments.” Registration Delay Payments shall be paid on the
earlier of (I) the last day of the calendar month during which such Registration Delay Payments are incurred and (II) the third Business Day after the event or failure giving rise to the Registration Delay Payments is cured. In the event
the Company fails to make Registration Delay Payments in a timely manner, such Registration Delay Payments shall bear interest at the rate of one percent (1.0%) per month (prorated for partial months) until paid in full. The parties agree that
the maximum aggregate Registration Delay Payments payable to an Investor under this Agreement, when aggregated with any Public Information Failure Payments payable pursuant to Section 7.6(b), shall be 10% of the aggregate Purchase Price
paid by such Investor pursuant to this Agreement. Furthermore, in no event shall the Registration Statement Delay Payments payable during any thirty (30) day period, which when aggregated with any Public Information Failure Payments payable
pursuant to Section 7.6(b) during such thirty (30) day period exceed one percent (1.0%) of the aggregate Purchase Price of such Investor’s Shares. In addition, and notwithstanding anything to the contrary contained herein,
if the Company has received a comment by the SEC requiring an Investor to be named as an underwriter in the Registration Statement (which notwithstanding the reasonable best efforts of the Company is not withdrawn by the SEC) and such Investor
elects in writing not to be named as a selling stockholder in the Registration Statement, the Investor shall not be entitled to any Registration Delay Payments with respect to such Registration Statement. 

(b) At any time during the period commencing on the six (6) month anniversary of the Closing Date and, with respect to those
Investors who are not “affiliates” of the Company (as such term is defined in Rule 144(a)(1)) and who did not acquire Shares from an “affiliate” of the Company during the immediately preceding ninety (90) day period, at such
time that all of the Shares can be sold without the requirement to be in compliance with Rule 144(c)(1) and otherwise without restriction or limitation pursuant to Rule 144(c), including, if applicable, Rule 144(i), if a registration
statement is not available for the resale of all of the Shares and the Company shall fail for any reason to satisfy the current public information requirement under Rule 144 (a “Public Information Failure”) then, as partial
relief for the damages to any Investor by reason of any such delay in or reduction of its ability to sell the Shares of such Investor (which remedy shall not be exclusive of any other remedies available at law or in equity), the Company shall pay to
each Investor an amount in cash equal to one percent (1.0%) of the aggregate Purchase Price of such Investor’s Shares on every thirtieth day (pro rated for periods totaling less than thirty days) after a Public Information Failure until
the earlier of (i) the date such Public Information Failure is cured and (ii) such time that such public information is no longer required pursuant to Rule 144 with respect to those Investors who are not “affiliates” of the
Company (as such term is defined in Rule 144(a)(1)) and who did not acquire Shares from an “affiliate” of the Company during the immediately preceding ninety (90) day period . The payments to which a holder shall be entitled pursuant
to this Section 7.6(b) are referred to herein as “Public Information Failure Payments.” Public Information Failure Payments shall be paid on the earlier of (I) the last day of the calendar

  
 27 

 
month during which such Public Information Failure Payments are incurred and (II) the third Business Day after the event or failure giving rise to the Public Information Failure Payments is
cured. In the event the Company fails to make Public Information Failure Payments in a timely manner, such Public Information Failure Payments shall bear interest at the rate of one percent (1.0%) per month (prorated for partial months) until
paid in full. The parties agree that the maximum aggregate Public Information Failure Payments payable to an Investor under this Agreement, when aggregated with any Registration Delay Payments payable pursuant to Section 7.6(a), shall be
10% of the aggregate purchase price paid by such Investor pursuant to this Agreement. Furthermore, in no event shall the Public Information Failure Payments payable during any thirty (30) day period, which when aggregated with any Registration
Delay Payments payable pursuant to Section 7.6(a) payable during such thirty (30) day period exceed one percent (1.0%) of the aggregate Purchase Price of such Investor’s Shares. 

7.7 Questionnaires. The Purchaser agrees to furnish to the Company completed questionnaires in the form attached hereto as
Appendix I at the Closing for use in preparation of the Registration Statement contemplated in Section 7.1. The Company shall not be required to include the Shares of the Purchaser in the Registration Statement and shall not
be required to pay a cash payment to such Purchaser pursuant to Section 7.6 so long as the Purchaser fails to furnish fully completed questionnaires at the Closing or does not respond to subsequent written requests for information by the
Company within two business days of such requests; provided that the Company shall be required to provide only two (2) such subsequent written request for information. 
 8. Broker’s Fee. The Purchaser acknowledges that the Company intends to pay to the Placement Agent a fee in respect of the sale of the Shares to the Purchaser. The Purchaser and the Company
agree that the Purchaser shall not be responsible for such fee and that the Company will indemnify and hold harmless the Purchaser Indemnified Persons against any losses, claims, damages, liabilities or expenses, joint or several, to which such
Purchaser Indemnified Person may become subject with respect to such fee. Each of the parties hereto represents that, on the basis of any actions and agreements by it, there are no other brokers or finders entitled to compensation in connection with
the sale of the Shares to the Purchaser. 
 9. Independent Nature of Purchasers’ Obligations and Rights. The
obligations of the Purchaser under this Agreement are several and not joint with the obligations of any Other Purchaser, and no Purchaser shall be responsible in any way for the performance of the obligations of any Other Purchaser under the
Agreements. The decision of each Purchaser to purchase the Shares pursuant to the Agreements has been made by such Purchaser independently of any other Purchaser. Nothing contained in the Agreements, and no action taken by any Purchaser pursuant
thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such
obligations or the transactions contemplated by the Agreements. Each Purchaser acknowledges that no other Purchaser has acted as agent for such Purchaser in connection with making its investment hereunder and that no Purchaser will be acting as
agent of such Purchaser in connection with monitoring its investment in the Shares or enforcing its rights under this Agreement. Each Purchaser shall be entitled to independently protect and enforce its rights, including without limitation the
rights arising out of this Agreement, and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose. 

  
 28 

 10. Notices. All notices, requests, consents and other communications hereunder shall
be in writing, shall be mailed by first-class registered or certified airmail, e-mail, confirmed facsimile or nationally recognized overnight express courier postage prepaid, and shall be deemed given when so mailed and shall be delivered as
addressed as follows: 
 if to the Company, to: 
 Acacia Research Corporation 
 500 Newport Center Drive, 7th Floor 

Newport Beach, CA 92660 
 Attention: 
 with a copy to: 

Stradling Yocca Carlson & Rauth 
 660 Newport Center Drive, Suite 1600 
 Newport Beach, CA 92660 

Attention: Mark L. Skaist, Esq. 

or to such other person at such other place as the Company shall designate to the Purchaser in writing; and 

if to the Purchaser, at its address as set forth at the end of this Agreement, 

with a copy to: 
  

					
		 	  
	 	
		 	  
	 	
		 	  
	 	
		 	  
	 	
		 	  
	 	

 or at such other address or addresses as may have been furnished to the Company in writing. 

11. Changes. This Agreement may not be modified or amended except pursuant to an instrument in writing signed by the Company and
the Purchaser. Any amendment or waiver effected in accordance with this Section 11 shall be binding upon each holder of any securities purchased under this Agreement at the time outstanding, each future holder of all such securities, and
the Company. 
 12. Headings. The headings of the various sections of this Agreement have been inserted for convenience
of reference only and shall not be deemed to be part of this Agreement. 
 13. Severability. In case any provision
contained in this Agreement should be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby. 

14. Governing Law; Venue. This Agreement is to be construed in accordance with and governed by the federal law of the United
States of America and the internal laws of the State of Delaware without giving effect to any choice of law rule that would cause the application of the laws of any jurisdiction other than the internal laws of the State of Delaware to the rights and
duties of the parties. 

  
 29 

 15. Counterparts. This Agreement may be executed in counterparts, each of which shall
constitute an original, but all of which, when taken together, shall constitute but one instrument, and shall become effective when one or more counterparts have been signed by each party hereto and delivered to the other parties. Facsimile
signatures shall be deemed original signatures. 
 16. Entire Agreement. This Agreement and the instruments referenced
herein contain the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor the Purchaser makes any representation, warranty, covenant
or undertaking with respect to such matters. Each party expressly represents and warrants that it is not relying on any oral or written representations, warranties, covenants or agreements outside of this Agreement. 

17. Fees and Expenses. Except as set forth herein, each of the Company and the Purchaser shall pay its respective fees and
expenses related to the transactions contemplated by this Agreement. 
 18. Parties. This Agreement is made solely for
the benefit of and is binding upon the Purchaser and the Company and to the extent provided in Section 7.3, any Person controlling the Company or the Purchaser, the officers and directors of the Company, and their respective executors,
administrators, successors and assigns and subject to the provisions of Section 7.3, no other Person shall acquire or have any right under or by virtue of this Agreement. The term “successor and assigns” shall not include any
subsequent purchaser, as such purchaser, of the Shares sold to the Purchaser pursuant to this Agreement; provided, however, it shall include purchasers of Shares if (i) the Investor agrees in writing with the transferee or assignee to assign
such rights, and a copy of such agreement is furnished to the Company within a reasonable time after such assignment; (ii) the Company is, within a reasonable time after such transfer or assignment, furnished with a duly executed Stock
Certificate Questionnaire from such transferee or assignee and written notice of (a) the name and address of such transferee or assignee, and (b) the securities with respect to which such rights are being transferred or assigned;
(iii) immediately following such transfer or assignment, the further disposition of such securities by the transferee or assignee is restricted under the Securities Act and applicable state securities laws; (iv) at or before the time the
Company receives the written notice contemplated by clause (ii) of this sentence, the transferee or assignee agrees in writing with the Company to be bound by all of the obligations of Investor under this Agreement; (v) such transfer shall
have been made in accordance with the applicable requirements of this Agreement; and (vi) such transfer shall have been conducted in accordance with all applicable federal and state securities laws. 

19. Further Assurances. Each party agrees to cooperate fully with the other parties and to execute such further instruments,
documents and agreements and to give such further written assurance as may be reasonably requested by any other party to evidence and reflect the transactions described herein and contemplated hereby and to carry into effect the intents and purposes
of this Agreement. 
 [Remainder of Page Left Intentionally Blank] 

  
 30 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly
authorized representatives as of the day and year first above written. 
  

							
		 		 	Acacia Research Corporation
				
		 		 	By:	 	  

		 		 	Name:	 	
		 		 	Title:	 	
			
	 Print or Type:
	 		 	
		 		 	  

		 		 	 Name of Purchaser

(Individual or Institution)

			
		 		 	  

		 		 	Jurisdiction of Purchaser’s Executive Offices
			
		 		 	  

		 		 	Name of Individual representing Purchaser (if an Institution)
			
		 		 	  

		 		 	Title of Individual representing Purchaser (if an Institution)
			
		 		 	  

		 		 	Number of Shares to Be Purchased
			
		 		 	 $

		 		 	Price Per Share in Dollars
			
		 		 	 $

		 		 	Aggregate Price
				
	 Signature by:
	 		 		 	
		 		 	Individual Purchaser or Individual representing Purchaser:
			
		 		 	  

				
		 		 	Address:	 	  

				
		 		 	Telephone:	 	  

				
		 		 	Facsimile:	 	  

				
		 		 	E-mail:	 	  

  
 31 

 EXHIBIT B 
 For purposes of the forms of opinions set out below, the following terms shall have the following meanings: 
 “Basic Documents” means the Purchase Agreement. 

“Company” means Acacia Research Corporation. 
 All other capitalized but undefined terms shall have the meanings ascribed to them in the Purchase Agreement. 
  

 
  

	 	•	 	 The Company has an authorized capitalization as set forth in the SEC Documents, and all of the issued shares of capital stock of the Company have been
duly authorized and validly issued, are fully paid and non-assessable, conform in all material respects to the description thereof contained in the SEC Documents and were issued in compliance with federal and state securities laws and not in
violation of any preemptive right, resale right, right of first refusal or similar right. All of the Company’s options have been duly authorized and validly issued, conform in all material respects to the description thereof contained in the
SEC Documents and were issued in compliance with federal and state securities laws. 

  

	 	•	 	 The issuance and sale of the Shares have been duly authorized on behalf of the Company. When delivered to and paid for by the Purchaser in accordance
with the terms of the Purchase Agreement, the Shares will be validly issued, fully paid and nonassessable; and the issuance of the Shares will not be subject to any preemptive or similar rights under the Delaware General Corporation Law or the
Company’s Amended and Restated Certificate of Incorporation or Amended and Restated By-laws. 

  

	 	•	 	 Each of the Basic Documents to which the Company is a party has been duly authorized and validly executed and delivered on behalf of the Company, and
is enforceable against the Company in accordance with its respective terms, except as such enforceability may be limited by (A) applicable bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium or similar laws from time to time
in effect affecting creditors’ rights and remedies generally and by general principles of equity (regardless of whether such principles are considered in a proceeding in equity or at law) and (B) public policy, applicable law relating to
fiduciary duties and indemnification and contribution and an implied covenant of good faith and fair dealing. 

  

	 	•	 	 Except for the approvals required by the Commission in connection with the Company’s obligations under the Purchase Agreement (including the
Registration Statement referenced therein) or otherwise obtained under the state securities laws (“blue sky” laws), or approvals required by applicable foreign securities laws or the Financial Industry Regulatory Authority, no consent,
approval, authorization or order of, or filing or registration with, any court or governmental agency or body having jurisdiction over the Company or any of its properties or assets is required is required in connection with the execution, delivery
or performance by the Company of any of the Basic Documents to which it is a party. 

  
 EXHIBIT B-1

	 	•	 	 the Company is not an “investment company” within the meaning of the Investment Company Act of 1940, as amended.

  

	 	•	 	 Assuming the accuracy of the representations and warranties of each Purchaser contained in the Purchase Agreement, the issuance and sale of the Shares
pursuant to the Purchase Agreement are exempt from registration requirements of the Securities Act of 1933, as amended. 

  

	 	•	 	 Such counsel has participated in conferences with officers and other representatives of the Company, representatives of the Company’s independent
public accountants, representatives of the Placement Agent and representatives of the Purchaser at which the contents of the Private Placement Memorandum and the documents incorporated therein and related matters were discussed and, although such
counsel need not pass upon and need not assume responsibility for the accuracy, completeness or fairness of the statements contained in the Private Placement Memorandum, on the basis of the foregoing, nothing has come to the attention of such
counsel that causes such counsel to believe that (i) the Private Placement Memorandum, at the Closing Date, contained an untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary to make
the statements therein, in the light of the circumstances under which they were made, not misleading (it being understood that such counsel need not express any opinion in this paragraph with respect to the financial statements and schedules, notes
thereto and other financial data derived therefrom, included in the Private Placement Memorandum). 

 Form of
Opinion of Stradling Yocca Carlson and Rauth 
 (i) The Company has been duly organized, is validly existing and in good
standing as a corporation under the laws of its jurisdiction of organization and is duly qualified to do business and in good standing as a foreign corporation in each jurisdiction in which its ownership or lease of property or the conduct of its
businesses requires such qualification, except where the failure to be so qualified or in good standing could not reasonably be expected to have a Material Adverse Effect. The Company has all power and authority necessary to own or hold its
properties and conduct the businesses in which it is engaged. 
 (ii) The Company has an authorized capitalization as set forth
in the SEC Documents, and all of the issued shares of capital stock of the Company have been duly authorized and validly issued, are fully paid and non-assessable, conform in all material respects to the description thereof contained in the SEC
Documents and were issued in compliance with federal and state securities laws and not in violation of any preemptive right, resale right, right of first refusal or similar right. All of the Company’s options have been duly authorized and
validly issued, conform in all material respects to the description thereof contained in the SEC Documents and were issued in compliance with federal and state securities laws. 

(iii) The Shares to be issued and sold by the Company pursuant to the Purchase Agreements have been duly authorized and, upon payment
and delivery in accordance with the Purchase Agreements, will be validly issued, fully paid and non-assessable and will conform in all material respects to the description thereof contained in the SEC Documents in respect of the Company’s
Common Stock. 

  
 EXHIBIT B-2

 (iv) There are no preemptive rights under federal law or under the Delaware General
Corporation Law to subscribe for or purchase the Shares. There are no preemptive or other rights to subscribe for or to purchase, nor any restriction upon the voting or transfer of, any of the Shares pursuant to the Company’s charter or by-laws
(or similar organizational documents) or any agreement or other instrument known to us. 
 (v) The Purchase Agreements and the
Letter Agreement (collectively, the “Transaction Agreements”) have been duly and validly authorized, executed and delivered by the Company. 
 (vi) The execution, delivery and performance of the Transaction Agreements by the Company, the consummation of the transactions contemplated by the Transaction Agreements and the application of the
proceeds from the sale of the Shares as described under “Use of Proceeds” in each of the Preliminary Private Placement Memorandum and the Final Private Placement Memorandum do not and will not (i) conflict with or result in a breach
or violation of any of the terms or provisions of, impose any lien, charge or encumbrance upon any property or assets of the Company, or constitute a default under, any indenture, mortgage, deed of trust, loan agreement, license or other agreement
or instrument known to us to which the Company is a party or by which the Company is bound or to which any of the property or assets of the Company is subject; (ii) result in any violation of the provisions of the charter or by-laws (or similar
organizational documents) of the Company; or (iii) result in any violation of any statute or any rule or regulation, or any order known to us issued by any court or governmental agency or body having jurisdiction over the Company or any of its
properties or assets. 
 (vii) Except for the registration of the Shares under the Securities Act in accordance with the
registration rights under the Purchase Agreements, and such consents, approvals, authorizations, registrations or qualifications as may be required under the Exchange Act, applicable state or foreign securities laws and the Financial Industry
Regulatory Authority in connection with the sale of the Shares by the Company pursuant to the Purchase Agreements, no consent, approval, authorization or order of, or filing or registration with, any court or governmental agency or body having
jurisdiction over the Company or any of its properties or assets is required for the execution, delivery and performance of the Transaction Agreements by the Company and the consummation of the transactions contemplated thereby. 

(viii) To our knowledge, except for the Purchase Agreements and as described in the SEC Documents, there are no contracts, agreements or
understandings between the Company and any person granting such person the right (other than rights which have been waived in writing or otherwise satisfied) to require the Company to file a registration statement under the Securities Act with
respect to any securities of the Company owned or to be owned by such person or to require the Company to include such securities in the securities registered pursuant to the Registration Statement or in any securities being registered pursuant to
any other registration statement filed by the Company under the Securities Act. 
 (ix) To our knowledge, except as described
in the SEC Documents, there are no legal or governmental proceedings pending to which the Company is a party or of which any property or assets of the Company is the subject that could reasonably be expected to have a Material

  
 EXHIBIT B-3

 
Adverse Effect or could reasonably be expected to have a material adverse effect on the performance of the Transaction Agreements or the consummation of the transactions contemplated thereby;
and, to our knowledge, no such proceedings are threatened or contemplated by governmental authorities or others. 
 (x) It is
not necessary in connection with the offer, sale and delivery of the Shares under the Purchase Agreements in accordance therewith to register the Shares under the Securities Act of 1933, as amended, it being understood that no opinion is expressed
as to any subsequent offer or resale of any of the Shares. 
 (xi) The Company is not, and after giving effect to the offer and
sale of the Shares to be issued and sold by the Company pursuant to the Purchase Agreements and application of proceeds as described in “Use of Proceeds” in each of the Preliminary Private Placement Memorandum and the Final Private
Placement Memorandum, will not be an “investment company” within the meaning of and subject to regulation under the Investment Company Act of 1940, as amended. 

  
 EXHIBIT B-4

 SUMMARY INSTRUCTION SHEET FOR PURCHASER 

(to be read in conjunction with the entire 
 Purchase Agreement which follows) 
  

	 	A.	Complete the following items on BOTH Purchase Agreements (Sign two originals): 

 

	 	1.	Signature Page: 

  

	 	(i)	Name of Purchaser (Individual or Institution) 

  

	 	(ii)	Name of Individual representing Purchaser (if an Institution) 

  

	 	(iii)	Title of Individual representing Purchaser (if an Institution) 

  

	 	(iv)	Signature of Individual Purchaser or Individual representing Purchaser 

  

	 	2.	Appendix I - Stock Certificate or Registry Questionnaire/Registration Statement Questionnaire: 

Provide the information requested by the Stock Certificate Questionnaire and the Registration Statement Questionnaire. 

 

	 	3.	Return BOTH properly completed and signed Purchase Agreements including the properly completed Appendix I (initially by facsimile with original by overnight delivery)
to: 

 Barclays Capital Inc. 
 745 Seventh Avenue, 5th Floor 
 New York, NY 10019 

Attn: Keith Canton 
 Facsimile: 212-520-9328 
 Email: keith.canton@barclayscapital.com 

 

	 	B.	Instructions regarding the transfer of funds for the purchase of Shares will be sent by facsimile to the Purchaser by the Placement Agent at a later date.

  

	 	C.	Upon the resale of the Shares by the Purchaser after the Registration Statement covering the Shares is effective, as described in the Purchase Agreement, the Purchaser
must deliver a current prospectus of the Company to the buyer (prospectuses must be obtained from the Company at the Purchaser’s request). 

 Appendix I 
 Page 1 of 3 
  

  
 STOCK CERTIFICATE OR REGISTRY QUESTIONNAIRE 
 Pursuant to
Section 3 of the Agreement, please provide us with the following information: 
  

							
	1.	  	The exact name that your Shares are to be registered in (this is the name that will appear on your stock certificate(s), if your Shares are to be certificated, or the name in which
the Shares are to be registered in the book entry registry, if your Shares are to be uncertificated). You may use a nominee name if appropriate:	  	  
	  	
				
	2.	  	The relationship between the Purchaser of the Shares and the Registered Holder listed in response to item 1 above:	  	  
	  	
				
	3.	  	The mailing address of the Registered Holder listed in response to item 1 above:	  	  
	  	
		  		  	  
	  	
		  		  	  
	  	
		  		  	  
	  	
				
	4.	  	The Social Security Number or Tax Identification Number of the Registered Holder listed in response to item 1 above:	  	  
	  	

 Appendix I 
  (Page 2 of 3) 
   

     

REGISTRATION STATEMENT QUESTIONNAIRE 
 In connection with the preparation of the Registration Statement, please provide us with the following information: 
 1. Pursuant to the “Selling Stockholder” section of the Registration Statement, please state your or your organization’s name exactly as it should appear in the Registration Statement:

  
  

 
  
 2. Please provide the number of shares that you or your organization will beneficially own immediately after Closing, including those Shares purchased by you or your organization pursuant to this Purchase
Agreement and those shares purchased by you or your organization through other transactions and provide the number of shares that you have or your organization has the right to acquire within 60 days of Closing: 

 
  
  

 
 3. Have you or your organization
had any position, office or other material relationship within the past three years with the Company or its affiliates? 

             Yes
                     No 
  If yes, please indicate the nature of any such relationships below: 
  

 
  

 
  

 
  

 
 4. Are you (i) an FINRA
Member (see definition), (ii) a Controlling (see definition) shareholder of an FINRA Member, (iii) a Person Associated with a Member of FINRA (see definition), or (iv) an Underwriter or a Related Person (see definition) with respect
to the proposed offering; or (b) do you own any shares or other securities of any FINRA Member not purchased in the open market; or (c) have you made any outstanding subordinated loans to any FINRA Member? 

  
  1

 Answer: [    ] Yes [    ] No If “yes,”
please describe below 
  
  

 
  
  

 
  

 
 5. Are you a broker or a dealer or
an affiliate of a broker or a dealer? See the appropriate SEC definitions of “broker,” “dealer,” and “affiliate” below. 
             
Yes                     No 
 If yes, please indicate the nature of any such relationship below: 
  

 
  

 
  

 
  

 
 If you are an affiliate of a
broker-dealer, please confirm that BOTH of the following are true: 
  

	 	•	 	 You purchased the shares which are covered by the Registration Statement in the ordinary course of business as an affiliate of a broker-dealer; and

  

	 	•	 	 At the time you acquired the shares or other securities which are covered by the Registration Statement, you had no agreement or understanding,
directly or indirectly, with any person to distribute such securities. 

             Both are
TRUE                     Either of the above are NOT TRUE 
 6. Please identify the natural person or persons who have voting and/or investment control over the Company’s securities that you own, and state whether such person(s) disclaim(s) beneficial
ownership of the securities. For example, if you are a general partnership, please identify the general partners in the partnership. 
  

 
  

 

  
 2 

 Appendix I 
 (Page 3 of 3) 
  

 Affiliate. A person that directly, or indirectly through one or more
intermediaries, controls, or is controlled by, or is under control with a broker or dealer. 
 Broker. Any person engaged
in the business of effecting transactions in securities for the account of others. 
 Dealer. Any person engaged in the
business of buying or selling securities for such person’s own account through a broker or otherwise. 
 FINRA
Member. The term “FINRA member” means any individual, partnership, corporation or other legal entity that is a broker or dealer admitted to membership in the Financial Industry Regulatory Authority, Inc. (FINRA Manual, By-laws Article
I, Definitions) 
 Control. The term “control” (including the terms “controlling,” “controlled
by” and “under common control with”) means the possession, direct or indirect, of the power, either individually or with others, to direct or cause the direction of the management and policies of a person, whether through the
ownership of voting securities, by contract, or otherwise. (Rule 405 under the Securities Act of 1933, as amended) 
 Person
Associated with a Member of FINRA. The term “person associated with a member of FINRA” means every sole proprietor, partner, officer, director, branch manager or executive representative of any FINRA Member, or any natural person
occupying a similar status or performing similar functions, or any natural person engaged in the investment banking or securities business who is directly or indirectly controlling or controlled by a FINRA Member, whether or not such person is
registered or exempt from registration with the Financial Industry Regulatory Authority, Inc. pursuant to its bylaws. (FINRA Manual, By-laws Article I, Definitions) 
 Underwriter or a Related Person. The term “underwriter or a related person” means, with respect to a proposed offering, underwriters, underwriters’ counsel, financial consultants and
advisors, finders, members of the selling or distribution group, and any and all other persons associated with or related to any of such persons. (FINRA Interpretation)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}]]